

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## Report to the U.S. Attorney General

by the Suspicious Orders Task Force  
(Comprehensive Methamphetamine Control Act of 1996)



Washington, D.C.  
October 1998

PLAINTIFFS TRIAL  
EXHIBIT

**P-02030\_00001**

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



---

## Table of Contents

I. Executive Summary

II. Background

III. Formation

IV. Task Force Activities

V. Recommendations

- A) Manufacturers and Importers
- B) Wholesale Distributors
- C) Retail Distributors
- D) Other Issues

VI. Dissenting Opinion / Recommendation

Appendix A - Exhibits

- I) Suspicious Orders Identification Criteria
- II) Suspicious Order Reporting System of 1998 (For use in automated tracking systems)
- III) Factors Which May Suggest a Suspicious Transaction at Retail

Appendix B - Model Program: Control and Minimization of Suspicious Orders for Bulk Chemical Importers, Manufacturers, and Distributors

Appendix C - The Comprehensive Methamphetamine Control Act of 1996 (MCA)

Appendix D - Task Force Charter

Appendix E - Task Force Membership List

Appendix F - Federal Register Notices

SOTF - Report: 2

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## Report to the U.S. Attorney General

by the Suspicious Orders Task Force  
(Comprehensive Methamphetamine Control Act of 1996).



Washington, D.C.  
October 1998

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



---

## Table of Contents

I. Executive Summary

II. Background

III. Formation

IV. Task Force Activities

V. Recommendations

- A) Manufacturers and Importers
- B) Wholesale Distributors
- C) Retail Distributors
- D) Other Issues

VI. Dissenting Opinion / Recommendation

Appendix A - Exhibits

- I) Suspicious Orders Identification Criteria
- II) Suspicious Order Reporting System of 1998 (For use in automated tracking systems)
- III) Factors Which May Suggest a Suspicious Transaction at Retail

Appendix B - Model Program: Control and Minimization of Suspicious Orders for Bulk Chemical Importers, Manufacturers, and Distributors

Appendix C - The Comprehensive Methamphetamine Control Act of 1996 (MCA)

Appendix D - Task Force Charter

Appendix E - Task Force Membership List

Appendix F - Federal Register Notices

SOTF - Report: 2

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**Report to the U.S. Attorney General  
by the Suspicious Orders Task Force**  
Comprehensive Methamphetamine Control Act of 1996

**I. Executive Summary**

To: Attorney General Janet Reno

Subject: Report of the Suspicious Orders Task Force

The Suspicious Orders Task Force (Task Force) was formed by charter upon your signature and subsequent filing with Congress on September 3, 1997. It implemented the mandate contained in Section 504 of Public Law 104-237, known as the Comprehensive Methamphetamine Control Act (MCA) of 1996, signed into law by President Clinton on October 3, 1996.

The charter required the establishment of a task force to prepare recommendations concerning additional guidelines to be used by the chemical industry in complying with 21 U.S.C. 830 (b)(1)(A). This statute requires that certain regulated transactions which are commonly referred to as suspicious orders must be reported to the Drug Enforcement Administration (DEA) in order to prevent the diversion of listed chemicals used in the production of illicit substances.

The Task Force was comprised of 21 industry, Federal, state and local law enforcement, and regulatory officials. It met on four occasions in meetings open to the public and conducted under the rules established by the Federal Advisory Committee Act (5 U.S.C. App. 2) in Washington, D.C.; San Diego, California; St. Louis, Missouri; and San Antonio, Texas.

The Task Force took this charge seriously and the members worked diligently in acquainting each other with the roles they play, the seriousness and nature of the illicit drug production in the United States and addressing proposals and recommendations as to how governments and industry can take actions to curtail access to chemicals and other laboratory supplies while assuring legitimate needs are served.

The Task Force developed proposals for identifying indicators of suspicious orders in the various segments of industry. It considered payment practices and unusual business practices in attempting to identify prima facie suspicious orders. The Task Force found the business and payment practices in the multiple layers of the import through retail

SOTF - Report: 3

United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



distribution chain varied so widely that labeling specific practices prima facie indicators was not possible. The approach chosen was to recommend that the factors in Appendix A need to be considered in the totality of the transaction's circumstances.

The Task Force concluded that a single listing of meaningful, numerical parameters would be difficult. For the majority of registrants, which do not have highly automated computer ordering and tracking systems, the indicators contained in Appendix A, Exhibit I represent expanded guidance to be considered. For the segments of industry who have highly automated ordering and tracking systems, the Task Force recommends a system which starts with quantifiable parameters which track frequency of orders, deviation from prior orders, and size of orders (See Appendix A, Exhibit II). This segment of industry represents the distributors who are the suppliers to the independent and major drug chains. The Task Force also developed recommendations at the retail level for recognizing suspicious transactions and suggested voluntary actions, already in use by some retail outlets, to minimize criminal access to chemicals while assuring availability for legitimate medical use (See Appendix A, Exhibit III). The Task Force discussed and considered effectiveness, costs, and feasibility for all parties in its deliberations and in its final selection of proposals, though not all questions as to cost were identifiable by this group. A follow-on report will be prepared to provide cost estimates, identifiable to DEA, state and local governments, and industry in order to implement the recommendations. This report will also provide the results of a look at additional quantifiable parameters that industry can use to identify suspicious orders. This report will be submitted to the Attorney General by November 1, 1998.

The Task Force requests your review and approval of the recommendations contained in Section V of this report. These recommendations fall in the following general areas:

- 1) Improve the guidelines as to the definition of "suspicious" in regards to listed chemicals. This involves publishing a more detailed list, or criteria, for defining "suspicious", and more detailed guidance in how to use the criteria.
- 2) Improve communication between industry, law enforcement and regulators. This involves improvements to DEA's Internet Web Site; a new periodical to be published by the DEA; and increased attention to suspicious orders at DEA sponsored conferences & working groups.

SOTF - Report

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



- 3) Improve information/data transfer. This involves employing technology that will streamline the process of identifying and reporting, to and within DEA, what appears to be a suspicious order. In short, computerizing the process.

SOTF - Report: 5



United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



## II. Background

In the early nineteen nineties, the United States began to experience a public health crisis due to the illegal production and abuse of methamphetamine. This plight created a groundswell of calls for additional government efforts to deal with the tremendous epidemic of illicit methamphetamine production and abuse. Further, this public health crisis has been fueled by a rapidly changing supply picture involving methamphetamine produced in both Mexico and the United States. Governments at all levels have reacted with new strategies and legislative initiatives. One critical element in those efforts has been a focus on restricting access to the chemical compounds necessary to produce methamphetamine and its chemically similar drug homologs, amphetamine and methcathinone.

The processes most frequently used in the illicit production of methamphetamine in the United States changed from an early reliance on the Phenyl-2-Propanone (P2P) synthesis, which was the technique used largely by outlaw motorcycle gangs, to those syntheses which used the chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The use of these readily available chemicals caused the production picture to rapidly change. Large criminal organizations based in Mexico and California emerged and began producing illicit methamphetamine both within Mexico and the western United States. The ready availability of these chemicals also gave rise to a tremendous number of smaller clandestine laboratories run by domestic criminals in a pattern of production and abuse that is still spreading eastward.

The laboratory activities controlled by the Mexican organizations focused on ephedrine acquired in bulk form. These materials were obtained from the international market until the end of 1995 by which time those supplies were largely curtailed through international cooperation in verifying the legitimacy of shipments. Within the United States, the controls initiated when Congress passed the Chemical Diversion and Trafficking Act (CDTA) in 1988, removed bulk ephedrine powder from the illicit supply being diverted from the commercial market. Drug products containing ephedrine, pseudoephedrine, and phenylpropanolamine play a dual role in this drama. These chemicals serve as precursors for the production of methamphetamine, amphetamine, and methcathinone, as well as appearing in over-the-counter (OTC) products approved by the FDA for treatment of coughs and colds. These products were exempted from control by the CDTA because of their legitimate role and because their diversion was not then perceived as a significant problem. But, because these products are largely sold "over-the-counter", and therefore readily available, they rapidly became the target of choice to supply the raw materials to the illicit market. Because of this exemption, domestic criminal

SOTF - Report



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



elements focused their attention on obtaining ephedrine tablets. A variety of "rogue" companies emerged that specialized in providing these tablets in large volumes.

With the passage of the Domestic Chemical Diversion and Control Act (DCDCA) in late 1993, the exemption for single entity ephedrine tablets was removed (effective in April 1994). Traffickers began a switch to the remaining exempted OTC products beginning in the fall of 1994. During 1995, and continuing to the present, the focus has been on obtaining those phenylpropanolamine, pseudoephedrine, and ephedrine combination products.

With the signing into law of the Comprehensive Methamphetamine Control Act (MCA) of 1996, the exemptions for ephedrine combination products were removed immediately and pseudoephedrine and phenylpropanolamine products were removed effective October 3, 1997. The passage of the MCA has begun to have positive effects in curtailing the supply available to criminal elements. Further, the MCA brought an existing control regime to a new set of legitimate handlers of controlled chemicals; those in the OTC supply chain. These newly regulated entities included chemical suppliers and pharmaceutical supply chains whose OTC product distribution had not previously been required to comply with Controlled Substances Act (CSA) List I controls.

Industry expressed concerns regarding statutory requirements to report to DEA what are commonly referred to as suspicious orders. Industry made requests to the Congress for additional guidelines and procedures to specifically define what constitutes a suspicious order and a request to explore development of an electronic means to transmit such reports. These concerns were included in Section 504 of the MCA establishing this Suspicious Orders Task Force.

SOTF - Report: 7

United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



### III. Formation

The Suspicious Orders Task Force was formed as a result of a mandate included in the Comprehensive Methamphetamine Control Act of 1996 (MCA), chemical control legislation amending the Controlled Substances Act of 1970 (CSA). Further, Section 504 of the MCA imposed on the Task Force the restrictions outlined in the Federal Advisory Committee Act (FACA) (5 U.S.C. App. 2).

While the findings of the Task Force may have more wide ranging applications, because of the nature of the enabling legislation, the Task Force limited its area of consideration to domestic issues regarding suspicious orders of List I and List II chemicals. The Task Force was structured to provide the Attorney General with a preliminary report containing the Task Force Operational Plan by October 3, 1997 and a report within two years after the date of enactment of the MCA (October 3, 1998).

The DEA's Office of Diversion Control (OD) was responsible for providing the necessary administrative and clerical support to the Task Force. Such support included, but was not limited to:

1. Arrangements for public meeting space
2. Photocopying
3. Note taking during meetings
4. Transcribing and final preparation of minutes and proposals
5. Preparation and dissemination of the required Federal Register notices
6. Preparation of required administrative reports (under FACA)

The administrative expenses of the Task Force were paid out of existing Department of Justice funds from DEA appropriations. Recurring expenses included, but were not limited to, the following:

1. Publicly accessible meeting space for all four full Task Force meetings.
2. Administrative preparation and maintenance of reports, records, statements, and working papers generated by the Task Force's activities.
3. Per diem and travel expenses for public sector members of the Task Force and administrative staff.
4. Human resource requirements which included three administrative staff; two part time assignments and one full time assignment.

Note: Private sector participant costs were borne by the participants and their respective employers.

SOTF - Report

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



All expenditures including per diem, travel expenses, other expenses, fees, and compensations were made in accordance with the limitations outlined in the FACA. Further, all members of the Task Force served at the discretion and pleasure of their respective employers.

The four Task Force meetings were held in geographically diverse areas to encourage interested public comment from the broadest number of those concerned with suspicious chemical orders. Meeting locations, based on the illicit methamphetamine production conditions existing at the time of the passage of the MCA, were: the west coast (San Diego, California); in the Midwest (St. Louis, Missouri); and on the east coast (Washington, D.C.). These meetings were held for the express purpose of gathering information by collecting data and hearing testimony from experts in law enforcement and industry. The fourth meeting was held in San Antonio, Texas, for the express purpose of drafting recommendations and composing this report.

The Chairman of the Task Force was the Chief of the Chemical Operations Section of DEA's Office of Diversion Control. In accordance with the FACA, the Chairman selected a Designated Federal Official (DFO) to oversee the operations of the Task Force from the administrative staff at DEA Headquarters. The DFO was a non-voting member of the Task Force.

The Task Force consisted of 21 voting members selected from law enforcement, regulatory agencies, and the chemical and pharmaceutical industries. Within the confines of the MCA and logistical and budgetary limitations, the Task Force consisted of:

- 1) Two members of the DEA investigative work force. These members were selected because of their knowledge of chemical and/or clandestine laboratory investigations.
- 2) One member from the United States Attorney's Office for the Southern District of California. This member was selected because of her expertise in prosecuting cases involving List I and II chemicals and clandestine laboratories.
- 3) Five members from State and local law enforcement. These members were selected from the nationally recognized International Association of Chiefs of Police (IACP), the National Association of Diversion Drug Investigators (NADDI), the California Bureau of Narcotics Enforcement (CA/BNE), the Missouri State Highway Patrol, and the Missouri Attorney General's Office.

SOTF - Report: 9

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



- 4) **Two members from regulatory agencies.** These members were selected from The National Association of Boards of Pharmacy (NABP) and the National Association of State Controlled Substances Authorities (NASCSA).
- 5) **Four members from the chemical industry.** These members were selected from the Chemical Manufacturers Association (CMA) and the National Association of Chemical Distributors (NACD).
- 6) **Five members from the pharmaceutical industry.** These members were selected from the wholesale and retail pharmaceutical marketing associations. The National Non-Prescription Drug Manufacturers' Association (NDMA), The National Community Pharmacists' Association (NCPA), The National Wholesale Druggists' Association (NWDA), The Food Marketing Institute (FMI), The National Association of Chain Drug Stores (NACDS) each provided members.
- 7) **Additional Membership.** At its inception, the Chairman retained the option of adding up to two additional members to the Task Force. The proposed composition and representation of the Task Force were made public through the Federal Register. While no one came forward in response to the announcement, testimony received during the meetings indicated the need for additional representation. After consultation with the other Task Force members and at the request of the American Wholesale Manufacturers' Association (AWMA), the Chairman added one additional member to the Task Force to represent the service merchandise industry (See Appendix E, Membership List)

#### Method of Operation

- 1) The Task Force operated in a round table fashion consisting of "a committee of the whole." This format did not require the formation of sub-committees and, due to the limited scope and resources of the Task Force, none was formed until the drafting of the finished report had begun.
- 2) The report contains a majority opinion and such minority opinion(s) as are deemed appropriate by the Task Force Chairman and the DFO. The majority opinion was determined by consensus of the majority of members.
- 3) The Task Force Chairman, in conjunction with the DFO, prepared, and circulated in advance, a meeting agenda, with time table, including relevant topics submitted by other Task Force members, any administrative matters slated for discussion and

SOTF - Report

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



clearly defining a limited time period to receive verbal statements from interested members of the public.

- 4) In accordance with the FACA, all meetings of the Task Force were open to the public with appropriate notices appearing in the Federal Register. Interested parties were permitted to attend the Task Force meetings, appear before the Task Force and present verbal and written statements. Any written statements submitted to the Task Force were disseminated to all Task Force members and made available to the attending public. Additionally, the public was offered the opportunity to sign up for distribution of those handouts that were not available at the meeting. All submissions were made a part of the meeting record. All verbal comments were recorded by court reporters and were made a part of the official record.
- 5) The first meeting included a statement as to the operation of the Task Force, its procedures, and agenda. Further, the first meeting included an ethics briefing. The second and third meetings included testimony by invited speakers and experts in clandestine laboratory investigations. Both of these meetings also included extensive testimony from the attending public. Discussions of presented materials included the attending public as well as the Task Force members. During the fourth meeting, the foundation for this report was drafted. Again, the attending public was allowed to observe and participate in the discussions.

SOTF - Report: 11



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



#### IV. Task Force Activities

The Suspicious Orders Task Force met on four occasions. The first meeting was held on December 16 and 17, 1997 in Arlington, Virginia. The second was held in San Diego, California on February 4 and 5, 1998. The third in St. Louis, Missouri on April 7 and 8, 1998. The fourth and final in San Antonio, Texas on May 19 and 20, 1998. The mandate that governed the formation of the Task Force (See Appendix C) is contained in Section 504 of the MCA. The responsibilities included:

- Developing proposals to define suspicious orders of listed chemicals,
- Developing quantifiable parameters which can be used by registrants in determining if an order is a suspicious order which must be reported to DEA, and
- Developing provisions as to what types of payment practices or unusual business practices shall constitute prima facie suspicious orders.

Further, the Task Force was tasked with evaluating the proposals with consideration for:

- Effectiveness,
- Cost and feasibility for industry and government, and
- Other relevant factors

Lastly, the Task Force was charged to address electronic reporting of suspicious orders to DEA.

The first issue considered by the Task Force was defining suspicious orders. The wide diversity of business activities represented by importers, manufacturers, wholesale distributors, and retail distributors was recognized early in the first meeting. A great portion of this first, and subsequent meetings, was devoted to member descriptions of the normal business activities and what they recognized as cause for suspicion in customer orders. At the first meeting a chart of business activity levels was drawn up to aid discussions. It was apparent that many segments had little knowledge and/or contact with other segments within the supply chain that handles regulated chemicals. The Task Force rapidly concluded that recognizing suspicious orders meant recognizing different circumstances at the differing levels of industry. No single definition of suspicious order nor prima facie payment or business practice was going to be attainable.

SOTF - Report:

United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



To address the issue of developing multiple layered suspicious order guidance a list of indicators keyed to various industry segments was prepared and reviewed by the Task Force. This list was developed to replace an earlier one, contained in the DEA *Chemical Handlers Manual*. The new list provides current, more specific indicators, as particularly requested by the newly covered wholesale portions of industry. The list was considered and referenced by all three drafting working groups at the San Antonio, Texas meeting and is presented in Appendix A, Exhibit I.

Industry suggested that this list be caveated to specifically articulate that these are merely indicators, no one of which may be a *prima facie* indicator that independently requires reporting to DEA, but needs to be viewed in the totality of the proposed order or transaction. The language of the caveat appears in recommendation A1. This recommendation commits all areas of industry to consider these indicators and DEA to be flexible in reviewing industry assessments of possible suspicious orders.

The industry segment which includes the highly automated wholesale drug distributors were specifically interested in quantifiable parameters with which they could use their computer power to assist in identifying possible suspicious orders in their Over-The-Counter (OTC) product lines. This segment of industry receives their orders virtually 100 percent electronically. These orders come from established customers or owned outlets, where the OTC product orders are a small portion of the items handled, representing small numbers of the total volume sent to any customer. They proposed using a modification of a system now in use for controlled substance suspicious order reporting. This system is contained in recommendation B1 and Appendix A, Exhibit II. This modified segment of the industry is not exempted from considering indicators contained in Exhibit I and requested a specific caveat, similar to the one above, which is contained in recommendation B2. Possible law enforcement requests for adjustment are addressed in recommendation B4.

The issues of suspicious orders in another OTC wholesale segment were highlighted by law enforcement testimony. Large orders, ranging from several to hundreds of cases per shipment, destined for outlets that do not also handle controlled substances, such as convenience stores, sundry outlets, and food marts have figured prominently in recent investigations. These volumes suggest that these customers are not operating at the retail level belying their outward appearance. This is the most prevalent area for diversion to illicit use. Two industry associations which represent businesses in this area of industry, testified that normal legitimate business practice would produce shipments in amounts similar to the highly automated wholesale drug distributors. Individual store orders should be enough to fill shelf stock only, because they are frequently serviced and have virtually

SOTF - Report: 13



United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



no "back room" storage space. Typically, OTC products would be only one among many items delivered by the wholesale company. This area of industry frequently does not have the same level of computer support as that referenced above. The suspicious order indicators in Appendix A, Exhibit I shall be used by this segment for guidance, while standard reporting requirements apply. Recognition that an alternate reporting system may be within the capabilities of some companies in this area is contained in recommendation B5.

The Task Force recognized that if any level of industry failed to exercise vigilance in identifying suspicious orders, the system would fail to deter diversion. The issue of companies functioning as brokers, potentially allowing both the distributor and the broker to evade responsibility, was pointed out. Law enforcement members cited a number of examples where this concern has already arisen. There is no broker category for domestic activities authorized by the Controlled Substances Act (CSA) and its implementing regulations. The Task Force working group at the wholesale level presented the proposal to require all persons or entities which operate at the wholesale level be governed by the same regulatory requirements that cover distributors at wholesale. See recommendation B6.

A significant issue arose which called into question the coverage of suspicious orders reporting at the retail level. The MCA defines most individual retail OTC distributions under the 24 gram threshold or in specified packaging as not being regulated transactions. The reporting requirement applies only to regulated transactions. This presents a rather large problem, as illustrated at the St. Louis meeting, which highlighted the prevalence of small methamphetamine laboratories in the Midwest. These laboratories are easily supplied with the necessary precursors with merely a few quick trips to retail outlets, buying only the maximum allowed by the 24 gram threshold at each location. This type of laboratory activity is also frequently encountered in other areas of the country. This includes California which is widely known for very large laboratories. The Task Force concluded it would be remiss if it didn't make recommendations in this highly vulnerable area.

The Task Force elected to recommend emulation of the many excellent voluntary initiatives undertaken by industry. These programs were described to the Task Force during testimony where the role for voluntary actions, that exceed mandated minimums, was highlighted by the importers, manufacturers, and wholesalers of bulk chemicals. The bulk chemical handlers reported that they have had programs to prevent diversion in place.

SOTF - Report

United States Department of Justice  
 Drug Enforcement Administration  
 Office of Diversion Control  
 Suspicious Orders Task Force



for many years and had participated in crafting the existing guidelines in DEA's *Chemical Handlers Manual*. Industry representatives described their programs as based on the "know your customer" principle of responsible business practice. Task Force members at the importer / manufacturer level provided a model control program (See Appendix B) and a description of their Responsible Care® program. One of the national drug store chains presented their retail sale limit program. The recommendations for voluntary programs contained in this report drew, in large measure, from these and other member's recommendations whose national associations are actively promoting such efforts to supplement regulatory requirements.

The first recommendation deals with publication by DEA of a list of suspicious order / transaction indicators. This document is specific to the retail setting and should be used in conjunction with the indicators in Appendix A, Exhibit I. This recommendation is found at C1 and the list is found in Appendix A, Exhibit III. (Additional explanatory text accompanies recommendation C1.) The Task Force recognized a concern that voluntary actions at the retail level to reduce access and discourage potential purchases for illicit use could have a potential implementation cost to the stores. These actions would have to be weighed against the abuse problem in the area. Some pharmacy outlets took these measures when the losses to "shelf sweepers" and shoplifters became severe. These measures are contained in recommendations C3 and C5. Cooperation between industry and law enforcement to develop local initiatives in areas of methamphetamine or other related drug issues is outlined in recommendation C4.

\*Issues dealing with the ease with which even mildly determined persons can currently obtain sufficient OTC products for illicit methamphetamine production generated a proposal to move pseudoephedrine OTC products into schedule V of the CSA. The majority of the Task Force felt that such a move could not be supported at the Federal level in light of enactment of the MCA. Most Task Force members felt that placing pseudoephedrine and other List I chemicals under more restrictive control was an action more appropriately taken by individual states. This is the only issue that drew formal dissenting comments. These are included in Section VI, Dissenting Opinion / Recommendation.

Presentation of U.S. import data for ephedrine and pseudoephedrine covering the years 1990 through 1996 generated considerable discussion. Especially notable is a sharp upturn in pseudoephedrine imports following the 1994 effective date of controls on single entity ephedrine products. The industry association representing manufacturers of national brands and large generic lines indicated their members saw no similar rise in production

SOTF - Report: 15

United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



and distribution during this period. This led to industry sponsored proposals regarding a medical needs assessment, an import reconciliation proposal, and the description of a reluctant but possible path to future quota action. These are found at recommendations D3, A2, and A4 respectively.

Another broad issue the Task Force identified was the continuing requirement for current information. Industry and law enforcement need to be informed in order to make progress in dealing with changing diversion patterns. The need for education within industry and the continual exchange of information between law enforcement and industry was addressed by the Task Force in a series of recommendations. While aware of the requirements for "public-private education" initiatives contained in Section 503 of the MCA, the Task Force recommendations were proposed to insure that the issue of suspicious orders remained in the forefront.

The recommendation contained in B7 articulates distributor responsibilities for monitoring trends in the ordering practices of their customers. Occurrences to be noted include any changes that might signal shifts in diversionary practices. These changes might indicate a switch to alternate chemicals or processes by the illicit laboratory operators. Further, it proposes to make DEA responsible for education and training of all parties as well as establishing a communications process to advise industry of these trends. The recommendation at C2 proposes that DEA publish a list of "Hot Zones" to advise industry and the public of where illicit methamphetamine production is a problem.

Continuing to address the issue of communication, the recommendation in D5 proposes that DEA consolidate the Chemical and Drug Industry conferences and cover a series of related topics of mutual interest. It also calls for a new DEA periodical publication focused on materials used in the clandestine production of illicit drugs.

The need to use modern communication techniques is addressed in recommendation at A3 and D6 which call for the upgrading of DEA's web-site to provide ready access to a variety of information of use to industry. One especially unique proposal appears in both recommendations. This proposal deals with publishing, on paper and electronically, a list of "prohibited persons" modeled after a similar list published by the Department of Commerce, Bureau of Export Administration. Such a listing would help satisfy at least a portion of industry's desire to have prima facie indication of suspicious transactions. The proposal assumes that due process and privacy considerations will be handled in proceedings prior to publication. The types of information to be published would include the identities of convicted illegal drug manufacturers; convicted chemical diverters; businesses prohibited from distributing chemicals because of revoked registrations;

SOTF - Report

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



businesses denied registration "for cause" or businesses under court ordered injunction. This information would be of direct benefit to distributors who are approached by these entities.

The mandate issue of electronic reporting was considered by the Task Force. It was concluded that designing such a system was beyond the expertise of the Task Force members. The discussion included a suggestion to build a system utilizing Internet access. Recommendations for a DEA follow-on process to build such a system were made at B3 and D4.

While the Task Force considered the cost of implementing these recommendations, it concluded that an accurate cost assessment was not feasible with the current membership. However, concerned that state authorities must participate in the suspicious orders process for it to work effectively and that funding at that level might not be sufficient to the task, the Task Force composed the recommendation in D2. It proposes that DEA form a working group(s) to identify state resources needed to implement the recommendations of the Task Force and identify available funding sources. Finally, recommendation D1 would task DEA with providing the Attorney General the detailed description and costs associated with resources required to implement any adopted recommendations. This will be addressed in the final report to be submitted by November 1, 1998.

A major change in the understanding of the roles that both industry and law enforcement play in the overall methamphetamine problem evolved throughout the four meetings. Industry acknowledged a new understanding of how their segments are subject to diversion and expressed a willingness to go beyond current efforts to curtail it. Law enforcement recognized the need to have regular dialogue with industry and each other and a new awareness of industries ongoing efforts. Industry segments handling non-regulated chemicals and laboratory supplies described by law enforcement witnesses were outside the current mandate. These items will be included in the Special Surveillance List mandated by the MCA and will require DEA to initiate future meetings with industry that also involve State and Local law enforcement and regulatory officials.

SOTF - Report: 17

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



NOTE: Reference Materials that were presented at the various meetings as well as the Transcripts of the meetings are available by contacting:

Suspicious Orders Task Force  
Designated Federal Official  
C/O Drug Enforcement Administration  
Office of Diversion Control  
Washington, D.C. 20537

SOTF - Report:



United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



## V: Recommendations

Because of the complexity of this issue, the Task Force concluded that the term "suspicious order" had different meanings at different levels of the manufacturing and distribution chain. Accordingly, the recommendations of the Task Force and the definition of "suspicious" are presented in a tiered fashion giving meaning to "suspicious" that is relevant to the different groups: Importers & Manufacturers; Wholesale Distributors; and Retail Distributors. While retailers were arguably not strictly included in the mandate that established the Task Force, the members felt that retail was an important part of the entire manufacturing and distribution chain and that they would be remiss in not making recommendations to help curtail suspicious transactions at that level. Additionally, the wholesale distributor to retail and retail distributor levels most commonly come into contact with individuals who would divert products used in the production of controlled substances. The Task Force additionally believed that it was necessary to develop some recommendations that would bolster the ability of DEA to provide continuing information to industry. Those recommendations are contained in Other Issues, Section D.

The recommendations that follow are divided into the different logical segments of the listed chemical distribution progression. The composition and wording of the recommendations were prepared by Task Force members most familiar with the areas of concern with input and review from the entire Task Force. Also included as Appendix B is a voluntary industry model program for reviewing List I chemical orders provided by one industry representative on the Task Force. A follow-on report will be prepared to provide cost estimates, identifiable to DEA, state and local governments, and industry in order to implement the recommendations. In addition, this report will provide the results of a look at additional quantifiable parameters that industry can use to identify suspicious orders. This report will be submitted to the Attorney General by November 1, 1998.

SOTF - Report: 19

United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



## A. Importers & Manufacturers

The Suspicious Orders Task Force recommends:

**A1** That the introduction to the DEA publication of "Suspicious Orders Guidelines" in the Chemical Handlers Manual be rewritten to include as follows:

"The following guidelines are intended to assist chemical manufacturers, distributors, wholesalers and retailers to be alert to suspicious orders involving listed chemicals. Consistent application of these guidelines will help industry assist DEA in preventing the diversion of legitimate chemical products to illegal drug manufacturing and use. The guidelines are intended to apply to all aspects of commercial chemical manufacturing and distribution. It is important that the guidelines are applied to the totality of any particular circumstances. No individual indicator listed below is independently a suggestion that a given order is suspicious and/or reportable to DEA. Questions concerning potentially suspicious orders should be directed to the local DEA office."

**A2** That DEA, in consultation with industry, design an effective means to require the accurate accounting of imports and exports of list one chemicals through routine and reliable industry reporting of differences and discrepancies between declared intentions to import and actual imports of listed chemicals.

*This recommendation reflects industry's intent and ability to assist DEA in reconciling actual imports with declared imports; to alert DEA to commercial circumstances susceptible to diversion; and responds to the Task Force's request for allowing DEA's accurate accounting of listed chemical imports, particularly ephedrine and pseudoephedrine. Current law does not require Importers or Exporters to notify DEA of undelivered, reduced, or canceled orders after making an initial declaration via DEA form 486 to Import or Export listed chemicals. This situation can effect DEA's assessments of potential diversion by producing erroneous statistics. Industry will continue to supply DEA information specific to individual shipments with differences and discrepancies.*

SOTF - Report:



United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



A3 That the Attorney General support additional DEA resources for information sharing and industry outreach, especially through improvements to the DEA web-site.

*In addition to the general goal of seeking better access to information from DEA, industry has frequently requested specific identification of persons whose activities are prima facie indicators which industry should regard as suspicious. One industry member informed the Task Force that currently, the Department of Commerce, Bureau of Export Administration, maintains a prohibited persons list on their Internet Home Page. These persons are forbidden from doing export business for a declared period of time. This may well serve as a model for informing legitimate business of persons and firms who have previously been convicted of illegal drug production activities or who are barred from engaging in regulated chemical transactions.*

A4 That the Attorney General not consider import quotas on ephedrine, pseudoephedrine and phenylpropanolamine without first producing specific and demonstrable evidence that import quotas will reduce diversion of these chemicals or products which contain these chemicals into clandestine laboratories for purposes of manufacturing illicit drugs. Such evidence shall, at a minimum, include an estimate of the legitimate domestic demand for products which contain List I chemicals, as well as analysis of the potential impacts on the availability of legitimate products which contain List I chemicals.

*Any consideration of possible import quotas should include a cost-benefit analysis assessing the impact to date of the MCA and the possible short and long term impacts of import quotas on commodity chemicals trade, consumer product prices, prevention and diversion programs and illegal drug manufacturing. While the Task Force suggests consideration of possible import quotas on certain chemicals, the Task Force acknowledges its lack of expertise on the possible effects and effectiveness of import quotas on illegal drug manufacturing and trade. The Task Force encourages completion of appropriate assessments and analyses in order to determine whether import quotas will merely provoke consumer and chemical price increases without combating diversion or demand.*

SOTF - Report: 21

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## B. Wholesale Distributors

The Suspicious Orders Task Force recommends:

**B1** That those in the wholesale drug distribution supply chain who are able use the DEA-approved Suspicious Order Monitoring System in use by wholesale drug distributors for controlled substances as enhanced by the Task Force in Appendix A, Exhibit II, for the reporting of potentially suspicious orders of listed chemicals including ephedrine, pseudoephedrine and phenylpropanolamine. DEA will be responsible, upon subsequent industry request, for providing the gram weight equivalent and base code ingredient data necessary to support the baseline suspicious order monitoring system for listed chemicals analogous to that currently in use to monitor controlled substance orders. For registrants in this supply chain who do not choose to use this data, Customer and Customer category average purchases or other DEA-approved methods will be used to identify orders which could be considered excessive or suspicious.

*This is basically what is done for Schedules II through V controlled substances for which base code ingredient and/or gram weight equivalent information is not available from DEA. This will be considered the baseline "reporting system." The specific parameters of the Baseline System are included as Appendix A, Exhibit II.*

*As a result of the Task Force work, an enhanced Suspicious Order Monitoring Reporting System (of 1998) was recommended by the DEA. Industry, using the historical data from their current (baseline) Suspicious Order Monitoring system, modeled the improved "targeting" of customers whose orders might be considered suspicious or excessive. The enhanced system significantly reduced the number of potentially suspicious or excessive purchase reports, thereby providing the DEA and other law enforcement agencies with a much sharper focus to detect those who may be engaging in illicit activity.*

*This enhanced suspicious order reporting system (the Suspicious Order Reporting System of 1998) will create reports when a customer's purchases exceed acceptable parameters in the "baseline" system two (2) consecutive months or in three (3) of any moving six (6) month period.*

SOTF - Report

United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



**B2** That those in the wholesale drug distribution supply chain who are able to support the automated, Suspicious Order Reporting System of 1998 requirements included in Appendix A, Exhibit I, shall not be deemed non-compliant solely on the basis that they fail to take into account one or more of the "indicators" included in Exhibit I.

*The Task Force looked at the provision in the regulation which directs registrants to report "extraordinary quantities" or "unusual or excessive losses" and other suspicious circumstances involving listed chemical transactions (21 CFR 1310.05). Industry leaders at this level commented that DEA has provided some guidance for industry on complying with the listed chemical suspicious order reporting requirement in the past, but much of this guidance is not applicable to many in the wholesale drug distribution supply chain segments. Incorporated here by reference and included as Exhibit I of the Task Force recommendations are enhanced DEA Chemical Handlers Manual indicators for the identification of orders which may be considered excessive or suspicious. It was recognized that these indicators may be more applicable to the operations of other chemical handlers, because many of these indicators are not usual and customary business practices of the legitimate wholesale drug distribution industry.*

*As an example, the typical national wholesale drug distributor:*

- (1) Receives virtually one hundred percent (100%) of their orders via electronic commerce (with no human interaction),*
- (2) Receives orders totaling 60,000 - 70,000 order lines nightly from 400 to 1,200 customers,*
- (3) Makes delivery within 12 - 18 hours of order receipt, and*
- (4) Distribution of regulated OTC chemical products in these order lines is usually a small portion and a small volume in any single customer order.*

*The typical customer base is: independent and chain retail drug stores and hospital/ institutional accounts. As a result of this level of activity and complexity, additional technology-based processes are necessary.*

**B3** That funding for and development of computer infrastructure sufficient to receive, process, analyze and redistribute time-sensitive enforcement information from suspicious order reporting to DEA field offices and other regulatory agencies and law enforcement groups for legal action be addressed within DEA's appropriations.

SOTF - Report: 23

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**B4** That, in exceptional cases, some individualizing of reports may be necessary to best address problems with listed chemical diversion in a particular area. To the extent agreed, changes to local/regional reporting are made at the request of the DEA and/or a state or local regulatory agency, the member of industry will seek, and DEA and/or the agency will provide, a letter stating the revised Suspicious Order Monitoring System meets the requirements of the DEA and/or the agency.

**B5** That in recognition of the fact that many wholesale distributors do not also distribute controlled substances, they may, with written permission of their field DEA office, Special Agent in Charge (SAC), maintain an alternative DEA approved reporting system. In no case are they exempt from the record retention, readily retrievable requirements. These companies shall use the indicators in Exhibit I as appropriate to their businesses as additional guidance in fulfilling their responsibilities to identify and report suspicious transactions.

**B6** That any person or entity that engages in any regulated transaction of List I chemicals with another entity (retailer/broker/dealer/distributor or a term with substantially the same meaning) engaged in the sale or distribution of a List I chemical to the general public shall be required to provide the same reports to DEA as the industry segment most generally described as wholesale distributor.

**B7** That wholesale distributors of chemicals and lab supplies, in addition to the indicators in the Chemical Handlers Manual, shall be cognizant of trends or changes in ordering patterns of their customers. These trend or/and changes may be indicative of a suspicious transaction as regulations and law enforcement efforts cause those involved in the manufacturing of illicit substances to adapt and replace existing processes requiring alternative chemicals or processes. DEA will proactively establish an education, training and communication process to advise industry on essential chemicals and equipment, questionable combinations of chemicals and identifiable or emerging patterns of diversion as they relate to illicit drug manufacturing activities.

SOTF - Report

United States Department of Justice  
 Drug Enforcement Administration  
 Office of Diversion Control  
 Suspicious Orders Task Force



### C. Retail Distributors

The Suspicious Orders Task Force recommends:

**C1** That DEA publish a list of indicators which aid retail entities to identify "suspicious transactions." (Our recommended list of indicators is presented in Exhibit III.) Because there is confusion as to whether sales in the retail OTC setting can fall within the statutory requirements of 21 U.S.C. 830 (b) (1), commonly referred to as "suspicious orders" which require specific reporting to DEA, statutory language should be clarified if it was Congress' intent to have transactions under threshold amounts or other retail sales fall within that definition.

*This Task Force was formed to provide updated definition of "suspicious orders" so that industry would know when such sales were occurring and meet their statutory obligation to report such orders. However, one industry witness contended that in the retail over-the-counter (OTC) context this process is unnecessary because the Comprehensive Methamphetamine Control Act of 1997 (P.L. 104-237) currently provides for precise and clear guidance concerning suspicious transactions in a retail store, meaning sub-threshold transactions are the only parameter that need be taken into account.*

*As specified in the statute approved by Congress, two important thresholds govern retail sales of listed chemicals to customers. Under the first threshold, retail stores that sell "ordinary over-the-counter pseudoephedrine or phenylpropanolamine product" are completely exempt from various DEA requirements including registration, record keeping and reporting. The term "Safe Harbor" is widely used by industry to describe the MCA definition of "ordinary over-the-counter". This exemption is applicable to those products that are packaged in blister packs of not more than two dosage units per blister and with no more than a total of three grams of base ingredients in the package. Additionally, the "safe harbor" provisions impose no limitations on the number of products that a customer may purchase in a single transaction.*

*The second threshold established by Congress covers OTC drug products containing pseudoephedrine or phenylpropanolamine that are not in "safe harbor" packaging and all combination ephedrine products. As specified by law, retail sales of combination ephedrine products and OTC drug products containing pseudoephedrine or phenylpropanolamine that are below the threshold of 24 grams in a single transaction are exempt. In contrast, the sale of these affected OTC drug products that are not in safe harbor packaging and combination ephedrine products*

SOTF - Report: 25



United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



*that are in excess of the 24 gram threshold in a single transaction, triggers a series of regulatory requirements for a retail store including registration, record keeping and reporting obligations.*

*While the law requires the reporting of some (suspicious) customer transactions, retail stores still need to be vigilant and exercise sound judgment in monitoring suspicious transactions or activities. The Task Force feels that it would be instructive to promulgate a list of factors which are indicators of suspicious transactions and the list is contained in Exhibit III. Industry members of the Task Force have noted that they are concerned about creating a list of factors which would mandate reporting to DEA on their part. The list presented in Exhibit II should be distributed or made known within the industry to enable retailers and their employees to recognize suspicious transactions and prevent possible diversion*

*It is important to note that a number of retail stores have already initiated voluntary policies which limit the number of products that can be purchased in a single transaction, and that retail stores understand that unusually large consumer purchases or theft of OTC products containing listed chemicals should be reported to DEA.*

**C2** That DEA publish a list of methamphetamine "hot zones" to make industry and the public aware of regions where methamphetamine is a problem.

*Methamphetamine manufacture and the accompanying diversion of ingredients, chemicals by manufacturers or their criminal partners are a significant problem in many areas of the United States, though, it is not yet a problem in every region. In order to make the DEA's and state and local law enforcement's knowledge of a regional methamphetamine problem known, it was suggested that DEA produce a list of methamphetamine "hot zones" which could serve to notify the retail industry in certain geographic areas where methamphetamine is a problem, that it may be necessary and appropriate to adopt measures to prevent diversion of ingredients from methamphetamine manufacture. The list could be regularly updated as identified criminal trends change. The list should be publicly available on the Internet, Federal Register, etc., to individual retail entities and retail associations alike so that legitimate industry can respond to this problem.*

SOTF - Report:

United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



C3 That, in regions or locations where methamphetamine is a problem, it is recommended that retailers consider actions which would control placement within the store of products containing regulated chemicals or materials used in the manufacture of methamphetamine. Such actions could include the following:

- 1) placing such items in highly visible locations within a store;
- 2) posting signs advising customers that identification may be requested if such items are purchased;
- 3) development of a store program where identification is requested of customers attempting to buy unusual quantities or suspicious combinations of such products;
- 4) limiting the amount of stock on the sales floor; and
- 5) placing such products in a restricted area of the store.

*The Task Force considered proposals relating to limitation of accessibility of chemicals on the sales floor. Industry representatives on the Task Force noted that placing OTC cough and cold preparations in restricted areas (e.g., in a restricted area of the store, behind the counter or in showcases or cages on the sales floor) would unduly inhibit consumers who have legitimate need for the products. In addition, they noted that due to the quantity and variety of such products on the market, most stores are not designed with enough physical space to place such products behind the counter. Finally, they noted that such a measure would place an enormous financial burden on the retail entity. However, the Task Force recognized the implications of this recommendation. These actions are intended to be voluntary and reflect industry endeavors already in place in some high problem areas. This commentary is intended to give voice and consideration to industry articulated concerns.*

*The Task Force also discussed suggestions relating to requesting identification at the point of sale, as that action often inhibits those intending to purchase items for diversion from doing so. It was noted that it would be difficult to identify criteria to evaluate whether such a sale should go forward. Factors such as name, age, or address would not be good measures. However, where there is a local problem and it appears that notifying customers that identification may be requested for OTC purchases of chemicals and products containing chemicals, posting signs advising customers of that fact may be effective in preventing diversion.*

SOTF - Report: 27



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**C4** That where there is a regional or local methamphetamine or other related drug problem, retail industry work closely with local law enforcement representative to address local needs and problems. Responsive, voluntary initiatives are recommended to present a rapid and effective measure to counter diversion.

**C5** That the following voluntary initiatives for retail stores that sell OTC products which contain List I chemicals be adopted:

1. Establish a policy whereby a retail store will only stock and sell OTC drug products that come in safe harbor packaging. Restrict (e.g., place in a restricted area of the store) or prohibit the sale of bulk 50-count or larger size packages.
2. Implement a policy at store level to limit the number of OTC products that a consumer may purchase in a single transaction. A number of retail chains have already instituted such policies on a voluntary basis, and business considering a voluntary program should look to other successful and effective programs instituted in their region or employed by similar type business.
3. Where feasible, implement a point-of-sale control system at cash registers. Separately or in conjunction with the "sale quantity limitations" program implemented above, stores may consider an electronic or "point of sale" check-out system that would display an operator message or void the transaction.
4. Post signs in retail stores to advise consumers and employees that the store reserves the right to limit the number of OTC products that may be purchased in a single transaction.
5. Review and, where appropriate, initiate programs that will enhance security at store level to minimize theft. Such programs could include source tagging of OTC drug products and the use of electronic surveillance cameras.
6. Limit sales of red phosphorous and iodine crystals. Monitor large sale of lye and iodine in retail stores. Educate sales force about illegitimate use of these products, as well as suspicious combination purchases.

SOTF - Report:

United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



7. Implement merchandising programs that would limit the number of OTC product packages that are on display on retail store shelves to discourage "shelf sweeping."
8. Initiate a program to monitor orders and shipments of OTC drug products from a company's distribution center to all company stores.
9. Promote educational programs for management and the work force, such as "Common Sense Compliance with the Methamphetamine Control Act of 1996", to help the retail community understand how they can work to ensure that legitimate OTC drug products are not diverted to clandestine labs for the illicit production of methamphetamine. Educate sales force regarding the illegitimate uses of List I chemicals, as well as the importance of identifying possible suspicious "combination purchases" of products.
10. Become involved with demand reduction efforts regarding the dangers of methamphetamine use, and work together to develop appropriate strategies to fight this serious drug abuse program.

*As has been discussed throughout the Task Force meetings, voluntary initiatives have been commenced in many segments of the retail industry. The Task Force feels that such voluntary initiatives should be encouraged and employed where appropriate. This listing of suggested initiatives is to be disseminated by DEA and state and local agencies. Communication techniques to be employed include publications, training programs, Internet Home Pages, and industry meetings. A number of industry associations have committed to disseminating this information to their members via their routine communications.*

SOTF - Report: 29

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



#### D. Other Issues

The Suspicious Orders Task Force recommends:

- D1** That DEA provide to the Attorney General the detailed description and costs associated with resources required to implement the recommendations of the Task Force.
- D2** That DEA working groups identify state resource needs to implement the recommendations of the Task Force and identify funding sources.
- D3** That the Attorney General convene a panel of medical and industry experts for the purpose of determining the legitimate medical need for products containing List I chemicals for the United States population.
- D4** That a follow-on working group (Federal, state, industry) be established for the purpose of: defining resources/cost/design specifications and system hardware support necessary to transmit/receive/assimilate/distribute suspicious order monitoring and other relevant information necessary to facilitate effective law enforcement efforts.
- D5** That DEA consolidate the Chemical and Drug Industry conferences currently hosted at 18 month intervals as well as increase and make routine communication between law enforcement representatives and representatives of both the chemical and pharmaceutical industries to ensure ongoing:

Information exchange

Education regarding:

- Trends
- Industry practices
- Prosecution successes
- DEA's publication of a periodical focusing on chemical and drug products and lab supplies used for the clandestine production of illicit drugs.

SOTF - Report:

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



D6 That the DEA Internet Web Site be upgraded to include:

- DEA responsibilities
- Guidance Documents
- DEA Forms
- Hot Areas - Trouble Spots, Current Issues, Chemical Changes, etc.
- Federal Register Notices
- Advanced Rule Making, if appropriate
- Registrant Verification
- FOIA
- List of List I Chemical Products including UPC and NDC identifiers
- Manufacturers' Voluntary Efforts
- A system, based on the principles currently in use by Food and Drug Administration (FDA) and Bureau of Export Control Administration (BXA), to provide notice of persons and firms who have been convicted of illegal drug production or prohibited from engaging in handling controlled chemicals. These listings would be made only after appropriate action has been taken which provides for due process. (*see recommendation A3.*)

SOTF - Report: 31

United States Department of Justice  
 Drug Enforcement Administration  
*Office of Diversion Control*  
 Suspicious Orders Task Force



## VI. Dissenting Opinion / Recommendation

The following letter was forwarded to Chairman Wolf by Task Force member Richard Markuson:

Dear Bill:

Sorry I will not be able to attend the Suspicious Orders Task Force meeting in San Antonio. As I indicated to you earlier, I will be attending the NABP national meeting.

Your letter indicates that work will begin on drafting the proposal to the Attorney General. Assuming this is the last meeting of the Task Force, I do have some concerns on our recommendations. There has been a lot of dialogue of what is meant by suspicious and what our specific task is to be. If we polled the members of the committee, I'm sure we would all agree, that we have a major problem with the illicit manufacturing of methamphetamine and amphetamine. We all know the problem precursors are ephedrine, pseudoephedrine and phenylpropanolamine [phenylpropanolamine]. The ephedrine has been controlled to a great extent, in a number of states, including Idaho, by placing it on prescription. The major problem now is pseudoephedrine, phenylpropanolamine and its widespread availability. I believe anybody purchasing these products for other than its intended medical use, and in particular in large quantities, becomes a suspicious order. I am also concerned that quantities of these products are packaged in bulk quantities of 100 or larger for retail sales. If we really want to get serious about this problem, then we have to address the retail sales of these products. I am not convinced that programs put in place at the retail level have been effective in deterring the sales of these products to individuals who wish to manufacture illicit drugs. How do we accomplish this and still have the products available to the public for their intended medical use? This to me is the question that needs to be answered, and should be addressed by this committee. There has been some discussion by the committee concerning retail sales but seems to stop short if the suggestion is made that sales should be restricted in some manner e.g. placing these products in Schedule V for OTC sales, even though this has occurred with ephedrine. Language could be included that would allow someone other than the pharmacist to make the sale. Combination products that meet certain criteria could be exempt from any record keeping requirements. We don't seem to have a problem requiring positive ID for tobacco and alcohol products. There is no reason the same thing can't occur when purchasing these products and still be available to the general public. This has become a national public health problem, let alone the cost of clean up for these labs has

SOTF - Report:

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



become astronomical, costing states millions of dollars. The bottom line should not be influencing what needs to be done to stop the production of these illicit drugs. We need to lay aside our self interests in this issue and get to the heart of the problem. It's time to do what needs to be done.

I appreciate the opportunity of working with the committee and look forward to some positive and worthwhile outcomes.

Please include this letter as my recommendations to the Attorney General.


Sincerely,

Richard K. Markuson, R.Ph.



Department of Public Safety  
**MISSOURI STATE HIGHWAY PATROL**  
Colonel Weldon L. Wilhoit, Superintendent

1510 East Elm Street  
Post Office Box 568  
Jefferson City, MO 65102-0568  
Phone: (573) 751-3313 (V/TDD) • FAX: (573) 751-9419



Mel Carnahan  
Governor

Gary B. Kempker  
Director

September 21, 1998

Mr. William J. Wolf Jr.  
Suspicious Orders Task Force  
Drug Enforcement Administration  
Washington, DC 20537

Dear Mr. Wolf:

I have reviewed a draft of the final report to the Attorney General concerning the recommendations and findings of the Suspicious Orders Task Force. I agree that the definition of "suspicious order" has different meanings at different levels. I support the Task Force's recommendations concerning importers and manufacturers and wholesale distributors; although, I do not believe the task force fulfilled its obligation by clearly defining reporting methodologies that are simple and quantifiable.

I must admit that I am very disappointed in the Task Forces's reluctance to provide a clear definition of a "suspicious order" at the retail level. During the time this Task Force has met I have witnessed the methamphetamine explosion move into the states of Oklahoma, Kansas, Iowa, Illinois and Arkansas. The meth production problem in Missouri has increased rapidly since the inception of this task force and has increased monthly since the Comprehensive Methamphetamine Control Act (MCA) of 1996 was signed on October 3, 1996. In simple terms, the Comprehensive Methamphetamine Control Act (MCA) has not adequately addressed the over-the-counter (OTC) sales of products containing pseudoephedrine or phenylpropanolamine. The language in the Suspicious Orders Task Force report fails to provide statutory recommendations concerning OTC products but rather ducks the issue by stating the OTC products have already been addressed by the MCA which provides for precise and clear guidance concerning suspicious transactions in a retail store. It is very obvious that this "precise and clear" guidance is not working.

It is true that many retailers have initiated some form of voluntary policy concerning sales limits on these products. I am sure these actions have been instrumental in reducing large scale diversion in some selected areas but most voluntary sales limits are still six times higher than the normal amount of product purchased by a legitimate consumer. This action requires the meth producer to




September 21, 1998  
Mr. William J. Wolf Jr.  
-2

expend more time and energy in procuring their precursors by making several trips to the store or by travelling to numerous locations and making the maximum purchase allowed at each until they accumulate the required amount of precursor to satisfy their needs. These retailers should be commended for taking a proactive approach but more stringent regulations are needed.

Missouri currently ranks as the number two state in meth lab seizures. Each month since 1995 this state has witnessed an increase in meth lab seizures. It is anticipated that somewhere between 700 and 1000 meth labs will be seized in Missouri in 1998. Although no firm statistic can be quoted, it appears that 95% of the pseudoephedrine/PPA diverted to meth lab production in Missouri is diverted at the retail level. I suspect these figures are also fairly accurate for the states surrounding Missouri. I would encourage the Attorney General to consider placing these products in Schedule V for OTC sales as has been done with ephedrine. Positive ID could be required as is now mandatory for tobacco and alcohol products.

In closing, some type of stringent retail regulation must be adopted to curtail this epidemic. Please accept this letter as a dissenting opinion as it pertains to the task force recommendation concerning retail level distribution. I would like to thank DEA for allowing me to be a part of this Task Force.

Sincerely,

  
JAMES F. KEATHLEY, Captain  
Division of Drug and Crime Control

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



# Appendix A

## EXHIBIT I

### Suspicious Orders Identification Criteria

Each regulated entity is most familiar with its customers and circumstances surrounding the orders it processes. The chemical industry must use its best judgment in identifying suspicious orders. The following are provided in order to assist the industry in identifying suspicious orders.

#### **ALL LEVELS/ALL CHEMICALS** (May not apply to all retail settings\*)

- ▶ New customer or unfamiliar representative or established customer who begins ordering listed chemicals.\*
- ▶ Customers who don't seem to know industry practice or who fail to provide reasons for an order at variance with accepted legitimate industry practice.
- ▶ Customer whose communications are not prepared or conducted in a professional business manner.\*
- ▶ Customer who provides evasive responses to any questions or is unable to supply information as to whether chemicals are for domestic use or for export.
- ▶ Customer who has difficulty pronouncing chemical names.
- ▶ New customers who don't seem to know Federal or state government regulations.\*
- ▶ Customer whose stated use of listed chemicals is incompatible with destination country's commercial activities or consignee's line of business.\*
- ▶ Customers who want predominantly or only regulated chemicals.
- ▶ Customers who want multiple regulated or surveillance list products, particularly if in contrast to customary use and practice.
- ▶ Customer who is vague or resists providing information about firm's address, telephone number, and reason for seeking that chemical.\*
- ▶ Customer who provides false or suspicious addresses, telephone numbers or references.
- ▶ Customer who is vague or will not furnish references for credit purposes.\*
- ▶ Customer who refuses or is reluctant to establish a credit account or provide purchase order information.\*
- ▶ Customer who prefers to pay by cashiers check, postal money order, etc.

SOTF Report Appendix A: 1

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**EXHIBIT I** (continued)

- ▶ Customer who desires to pay cash.\*
- ▶ Customer who wants to pick up the chemicals outside of normal practice in the suppliers experience.
- ▶ Customer with little or no business background available.\*
- ▶ An established customer who deviates from previous orders or ordering methods.
- ▶ Customers who want airfreight or express delivery.
- ▶ Customers who want chemicals shipped to PO Box or an address other than usual business address. (e.g. residence address)
- ▶ Customer using a freight forwarder as ultimate consignee.
- ▶ Customer who requests unusual methods of delivery or routes of shipment.
- ▶ Customer who provides unusual shipping, labeling, or packaging instructions.
- ▶ Customer who requests the use of intermediate consignees whose location or business is incompatible with the purported end users nature of business or location.
- ▶ Above threshold hydrochloride Gas or Iodine sales to a non-commercial customer.

**DISTRIBUTOR (Non-retail) REGULATED OTC PRODUCTS**

- ▶ Customers who don't want to tell you what area they will resell into.
- ▶ Customers who don't want to tell you in what volumes they will resell.
- ▶ Customers who refuse to tell you who their customers are.
- ▶ Customers who don't have limits on resales.
- ▶ Customers who push to buy more than your sales limit.
- ▶ Customers who repeatedly buy your sales limit at the shortest interval you set.
- ▶ Customers who don't know what his customers limits are on individual resales.
- ▶ Customers who resell to non-traditional outlets for regulated OTC products. e.g. hair salons, head shops, drug paraphernalia stores, liquor stores, record stores, video shops.
- ▶ Customers who resell large volumes into the "independent convenience store" market.
- ▶ Any customer who asks for large bottle sizes, 60 count or higher.
- ▶ Customers who buy only the largest size available.
- ▶ Customers that don't sell other pharmaceutical products or appear to sell those other products in token amounts.
- ▶ Any customer that resells multiple cases that flow through to individual retail outlets.

SOTF Report Appendix A: 2

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**EXHIBIT I** (continued)

- ▶ New customers who want to sell regulated OTC products into California, Arizona, Nevada, Oregon, Utah, Washington, New Mexico, Texas, Kansas, Missouri, Arkansas,
- ▶ Any customer who wants to sell to an outlet relocated from California, Missouri, or Kansas to any of the states identified in the prior sentence.
- ▶ Any customer who wants to export, particularly to Mexico, Canada, or Southeast Asia.
- ▶ Customers who will not provide you with evidence of registration with DEA. (Or having applied by the following deadlines: Nov 13, 1995 for single entity ephedrine; July 12, 1997 for ephedrine combinations products; Dec 3, 1997 for pseudoephedrine and phenylpropanolamine products.)
- ▶ Customers who will not provide you with evidence of applicable state registrations/licenses.
- ▶ Customers who sell mail order and who don't report sales to DEA monthly. (Note they must also be registered.)
- ▶ Nominal retail customers who sell above the Federal, "Retail," 24 GM individual sale limits.

**WHOLESALE DRUG DISTRIBUTION INDICATORS**

- ▶ Individual pharmacies that intend to export.
- ▶ Individual pharmacies or chains that won't set a voluntary limit for individual sales at some fraction of the Federal limit to qualify as a retail outlet.
- ▶ Pharmacies that stock large shelf volumes in stores that have repeated thefts or other sales problems.

SOTF Report Appendix A: 3

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## EXHIBIT II

### SUSPICIOUS ORDER REPORTING SYSTEM OF 1998 For Use in automated tracking systems

The Current Calculation Being Used  
for List I Chemicals and Schedule II - V Controlled Substances

#### Terms & Definitions

This formula is used to calculate the quantity which, if exceeded in one month, constitutes an order which may be considered excessive or suspicious.

- 1) Add purchase quantities for the last 12 months for all customers within same Distribution Center and for customer type (Hospital, Pharmacy or Other) for any List I chemical containing item stocked by the Distribution Center.
- 2) Add Customer months for every record used in above total. (Months within the last 12 that customer purchases of the item were not zero).
- 3) Divide total quantity purchased by the total customer months.
- 4) Then multiply by the factor below to give the maximum amount that the customer can order per month before showing up on the suspicious order report.

Note: Factor equals 3 for C-II and C-III Controlled Substances Containing List I Chemicals and 8 for C-III N-V Controlled Substances and non-Controlled OTC products containing List I chemical items.

- 5) At the end of each month, a report will be transmitted to DEA (separate reports for List I Chemicals and Schedule II - V Controlled Substances) of all purchases of List I Chemicals and/or C-II-V Controlled Substances and List I containing OTC items by any customer whose purchase quantities exceed the parameters (above) any (2) consecutive months or in three (3) of any moving six (6) month period.

Using a computer to manage and report on high volume transaction business activities with extremely short order cycles times (receipt to delivery) is the only viable, cost effective methodology for the reporting of orders which may be considered excessive or suspicious.

SOTF Report Appendix A: 4



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**EXHIBIT III**

**Factors which May Suggest a Suspicious Transaction**

**Retail Level - Regulated Products and/or Combination Purchases**

- OTC customers who ask for more than the transaction limit in effect.
- Customers who are part of a group, each of whom buys the transaction limit.
- Customers who buy the transaction limit on the same day and/or repeatedly within a few days.
- Customers who buy only the largest size available at the transaction limit.
- Customers who buy other methamphetamine processing products at the same time as the regulated products (alcohol, Coleman fuel, acetone, road flares, drain cleaners, iodine, muriatic acid, rock salt, starting fluid (ether), dry gas (alcohol), coffee filters, large amounts of matches, etc.).
- Customers who indicate they will resell or export.
- Iodine customers who don't have a legitimate reason for the purchase or who don't have an articulable reason for the volume requested.
- Customers who purchase three or more of the following products in combination: alcohol, Coleman fuel, acetone, road flares, drain cleaners, iodine, muriatic acid, rock salt, starting fluid (ether), dry gas (alcohol), coffee filters, large amounts of matches, etc.
- Customers who purchase Iodine crystals or pellets with any other item from the surveillance list.
- Customers who purchase hydrogen peroxide and over four fluid ounces of tincture of iodine.
- Customers who want to purchase red phosphorous or iodine and any other item from the surveillance list.
- Customers who want to pay cash when other forms of payment would be customary.

There may be a legitimate explanation for a purchase that presents one or more of these factors. The list is presented as a guide to instruct retailers and their employees as to which transactions may be suspicious.

SOTF Report Appendix A: 5



United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



## Appendix B

The following is an industry suggested model program for evaluating chemical orders to determine if they are reportable as suspicious orders:

### CONTROL AND MINIMIZATION OF SUSPICIOUS ORDERS FOR BULK CHEMICAL IMPORTERS, MANUFACTURERS AND DISTRIBUTORS

#### Overview

Proper identification of suspicious orders for bulk chemical importers, manufacturers and distributors should involve the establishment of an "approved customer list" for customers who are eligible to receive List I chemicals, and the development of attendant procedures relating to, *inter alia*, list maintenance, and suspicious orders. In particular, a system should be developed to monitor the approved list, and, for each order, review a list of order characteristics which would categorize the order as suspicious.

#### System Characteristics & Review

A multi-part control effort is necessary to minimize sales of List I chemicals to anyone but "legitimate" pharmaceutical manufacturers, and other select customers. The cornerstone of this effort should consist of the customer approval process. If a completely new customer attempts to order any List I chemical, a brief information package should be developed for an independent approval of the customer. Included in the approval should be the designation of approved ship-to locations. If an existing, approved customer wishes to add a new ship-to location, an independent approval of this new location should be made pursuant to the attached process.

#### Factors and Considerations for Approval

The following should be considered "red flags" in the approval process, and should place the company on notice of the potential for diversion by a customer.

- ✓ A customer who is vague about its firm's address, telephone number, and reason for desiring a listed chemical.
- ✓ A customer who will not furnish references or who is vague about furnishing references for credit purposes.
- ✓ A customer who desires listed chemicals for reasons at variance with accepted legitimate industry practice.
- ✓ A customer who is not a member of a trade, professional, or business association.

SOTF Report Appendix B: 1

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



- ✓ A customer who furnishes false or suspicious addresses, telephone numbers, or references.
- ✓ A customer who refuses or is reluctant to establish a credit account or provide purchase order information.
- ✓ A customer with little or no business background information available.
- ✓ A customer whose communication either by telephone, mail, or other means is not conducted or prepared in a professional business manner.
- ✓ A customer who purchases unusual quantities or combinations of chemicals or glassware in contrast with customary practice and usage.
- ✓ A customer whose stated use of listed chemicals is incompatible with destination country's commercial activities or consignee's line of business.
- ✓ The use of intermediate consignee(s) whose location or business is incompatible with the purported end user's nature of business or location.

#### Detailed Approval Considerations

All persons and entities requesting receipt of any quantity of a List I chemical should first be approved to receive such material. Any new ship-to address should be considered a new customer for purposes of these guidelines.

#### Classes of Customers

Potential recipients of List I chemicals should be placed into four categories:

- Approved customers. These are customers authorized to receive List I chemicals on an ongoing basis.
- Manufacturing requesters. This category includes any person or entity requesting to receive List I Chemicals for the purpose of manufacturing a product using the material. In general, such requesters can be further categorized into known manufacturers and non-known manufacturers. The screening process for these sub-categories should differ to some degree, and is discussed below.
- Research requesters. This category includes any research and/or evaluation concern, including University researchers, commercial labs, R&D operations within manufacturing companies, and other such organizations.
- Other requesters. Entities requesting to acquire List I chemicals which are not included in any of the preceding three categories, such as law enforcement agencies, educational organizations, freight forwarders, redistributors, etc.

SOTF Report Appendix B: 2

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



**Recommended Procedure**

The following information should be gathered prior to the investigation process:

- 1) Requester Name
- 2) Requester Address
- 3) Requester Corporate Affiliation(s)
- 4) Officer(s) of any concerned Corporate Entity
- 5) Material Delivery Address
- 6) Copy of Requester's DEA License or copy of Application
- 7) Requester's statement of end-use signed by an Officer of the Corporation
- 8) List of product(s) to be produced using requested material
- 9) Sample(s) of said product label(s)
- 10) Requester's business references (at least three)
- 11) Requester's banking references
- 12) Statement of how the customer was acquired
- 13) Statement of business unit's knowledge of the requester's business
- 14) Type and amount of material requested
- 15) Any unusual terms requested, i.e., immediate shipment, delivery to a freight forwarder, etc.

The company's credit department, or appropriate function, should provide the following information:

- 1) Credit decision and line extended
- 2) Credit report (Dunn & Bradstreet) produced within the preceding 90 days
- 3) Statement of any previous credit experience with this customer or related corporate entity
- 4) Primary Screening

Primary screening consists of the following:

- Is the requester a known company in the business of making a product containing the requested material? If so, call a developed point of contact (POC) and verify the information contained in the application.

SOTF Report Appendix B: 3

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



- Is the requester an existing customer for List I chemicals, and now requesting a different ship-to destination? If so, call the customer POC and confirm the legitimacy of the order.
- Is the requester a known research entity, such as a major University? If so, call the Research facility parent corporation's Director of Security to confirm the legitimacy of the order. In the case of a University, call to the Office of the Chairman of the appropriate department, usually Chemistry.
- Is the requester a subsidiary of an existing List I chemical customer, or of a known manufacturer? If so, call the customer POC and confirm the legitimacy of the order.
- Is all information contained in the request file within normal parameters? The following norms apply:

Requester Name - should be readily available from other sources and should match the Dunn & Bradstreet report.

Requester Address - should match the Dunn & Bradstreet report.

Requester Corporate Affiliation(s) - should match the Dunn & Bradstreet report.

Officer(s) of any concerned Corporate Entity - should match the Dunn & Bradstreet report, and should be verified through the appropriate State Department of State.

Material Delivery Address - should appear on the Dunn & Bradstreet as the principal or an additional site for the company, and the address should be appropriate to the statement of use. For example, if the request is for a manufacturing quantity, the delivery address should not be a lab.

Copy of Requester's DEA License - must be valid for the material requested, for the disposition requested. The requested ship-to address should match the license address. In general, very few entities have a license to export List I chemicals, and so disposition requests for delivery to shipping points and freight forwarders are suspect.

Requester's statement of end-use - must be unambiguous. "To manufacture a pharmacological preparation" or such language is unacceptable. The specific product, or the major company for whom toll manufacturing is being done, should be cited. In cases where the requester claims to be tolling, the relationship should be verified by contacting the major manufacturer in question.

List of product(s) to be produced - will be a recognizable product, something the supplier company should be familiar with.

SOTF Report Appendix B: 4



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Sample(s) of product label(s) - will be recognizable and state the presence of the requested material in the ingredients portion of the label. The label should agree with the name of the entity requesting the material or the entity which the requester asserts is the principal customer (in tolling operations).

Requester's Business references (should request three references) - Should be consistent with the requester's size and business.

Requester's Banking References - Should give the name of a particular bank officer and be consistent with the Dunn & Bradstreet report.

Statement of how the customer was acquired - If the customer was solicited by supplier's sales force, the sales person should provide specific information about the requester.

Statement of supplier's knowledge of the requester's business -- supplier's POC should advise as to the nature of the customer's business and stature in the industry, if known. If the requester is not known in the industry, the supplier should so state.

Type and amount of material requested - Should be consistent with the size of the requester's business, the stated end-use, and the product label.

There should be no unusual terms requested, i.e., immediate shipment, delivery to a freight forwarder, etc.

If, after a primary screening, there are still unresolved issues with the request, the supplier will begin a detailed evaluation.

#### **Detailed Evaluation**

Detailed evaluation consists of the acquisition of independent verification of as much of the request file information as possible and necessary. In performing a detailed evaluation, the following steps will be taken, in sequence, until such time as the Security Manager has reason to believe that the order is legitimate or has reason to believe that the order is inappropriate. The steps are:

Contact any other corporation security department which may have specific information on, or knowledge of, the requester.

Contact the DEA office (compliance) in the geographical region of the ship-to address. Discuss the request with the compliance officers at that office for their input.

SOTF Report Appendix B: 5

United States Department of Justice  
Drug Enforcement Administration  
Office of Diversion Control  
Suspicious Orders Task Force



Contact references provided in the application. Verify information provided, especially that all principles of the business entity have been disclosed.

Determine if the ship-to address site has ever been visited by a supplier salesperson. If so, interview that individual.

The application should be rejected at any point in the evaluation process if there are indications of inconsistencies in the information provided, invalid licenses, or other disqualifying information. Rejected applications should be so endorsed. Apparent attempts to divert should be reported to appropriate authorities.

#### Factors and Considerations for Individual Transaction Review

Sales representatives or order processing personnel must be trained to look for suspicious transactions *even with* approved customers. Specific transactional "red flags" are as follows:

The order is substantially greater than orders previously received from the customer.

The order is received more frequently than previous orders.

The size or frequency of such order is inconsistent with the known nature of the customer's business.

The customer is offering an unusual method of payment.

The customer is offering to pay a price substantially in excess of the normal market.

The customer is requesting delivery to an unknown site, or to a site different than that normally shipped to, or to a location that is not a known manufacturing site for finished pharmaceuticals.

The customer is indifferent to grade or particle size.

The customer desires to pay cash and wants to pick up the chemical(s).

An established customer deviates from previous orders or ordering methods.

An unfamiliar representative of an established customer orders listed chemicals.

SOTF Report Appendix B: 6

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



The customer who has difficulty in pronouncing chemical names.

The customer wants a listed chemical shipped to a post office box or address other than the usual business address.

The customer requests unusual methods or routes of shipment or who provides unusual shipping, labeling or packaging instructions.

The customer prefers to pay by cashier's check, postal money order, etc.

The customer proposes using a freight forwarder as ultimate consignee.

The customer, whose communication either by telephone, mail, or other means, is not conducted or prepared in a professional business manner.

The customer purchases unusual quantities or combinations of chemicals or glassware in contrast with customary practice and usage.

The customer's stated use of listed chemicals is incompatible with destination country's commercial activities or consignee's line of business.

The customer's use of intermediate consignee(s) whose location or business is incompatible with the purported end user's nature of business or location.

SOTF Report Appendix B: 7



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## Appendix C

The Comprehensive Methamphetamine Control Act of 1996  
(MCA)

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3099

Public Law 104-237  
104th Congress  
S. 1965

## An Act

To prevent the illegal manufacturing and use of methamphetamine.

*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*

### SECTION 1. SHORT TITLE AND TABLE OF CONTENTS.

(a) SHORT TITLE.—This Act may be cited as the "Comprehensive Methamphetamine Control Act of 1996".

(b) TABLE OF CONTENTS.—The table of contents for this Act is as follows:

Sec. 1. Short title and table of contents.

Sec. 2. Findings.

### TITLE I—IMPORTATION OF METHAMPHETAMINE AND PRECURSOR CHEMICALS

Sec. 101. Support for international efforts to control drugs.

Sec. 102. Penalties for manufacture of listed chemicals outside the United States with intent to import them into the United States.

### TITLE II—PROVISIONS TO CONTROL THE MANUFACTURE OF METHAMPHETAMINE

Sec. 201. Seizure and forfeiture of regulated chemicals.

Sec. 202. Study and report on measures to prevent sales of agents used in methamphetamine production.

Sec. 203. Increased penalties for manufacture and possession of equipment used to make controlled substances.

Sec. 204. Addition of iodine and hydrochloric gas to list II.

Sec. 205. Civil penalties for firms that supply precursor chemicals.

Sec. 206. Injunctive relief.

Sec. 207. Restitution for cleanup of clandestine laboratory sites.

Sec. 208. Record retention.

Sec. 209. Technical amendments.

Sec. 210. Withdrawal of regulations.

### TITLE III—INCREASED PENALTIES FOR TRAFFICKING AND MANUFACTURE OF METHAMPHETAMINE AND PRECURSORS

Sec. 301. Penalty increases for trafficking in methamphetamine.

Sec. 302. Enhanced penalties for offenses involving certain listed chemicals.

Sec. 303. Enhanced penalty for dangerous handling of controlled substances: amendment of sentencing guidelines.

### TITLE IV—LEGAL MANUFACTURE, DISTRIBUTION, AND SALE OF PRECURSOR CHEMICALS

Sec. 401. Diversion of certain precursor chemicals.

Sec. 402. Mail order restrictions.

### TITLE V—EDUCATION AND RESEARCH

Sec. 501. Interagency methamphetamine task force.

Sec. 502. Public health monitoring.

Sec. 503. Public-private education program.

Sec. 504. Suspicious orders task force.

4205



PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3100

**SEC. 2. FINDINGS.**

The Congress finds the following:

(1) Methamphetamine is a very dangerous and harmful drug. It is highly addictive and is associated with permanent brain damage in long-term users.

(2) The abuse of methamphetamine has increased dramatically since 1990. This increased use has led to devastating effects on individuals and the community, including—

(A) a dramatic increase in deaths associated with methamphetamine ingestion;

(B) an increase in the number of violent crimes associated with methamphetamine ingestion; and

(C) an increase in criminal activity associated with the illegal importation of methamphetamine and precursor compounds to support the growing appetite for this drug in the United States.

(3) Illegal methamphetamine manufacture and abuse presents an imminent public health threat that warrants aggressive law enforcement action, increased research on methamphetamine and other substance abuse, increased coordinated efforts to prevent methamphetamine abuse, and increased monitoring of the public health threat methamphetamine presents to the communities of the United States.

## **TITLE I—IMPORTATION OF METH- AMPHETAMINE AND PRECURSOR CHEMICALS**

### **SEC. 101. SUPPORT FOR INTERNATIONAL EFFORTS TO CONTROL DRUGS.**

The Attorney General, in consultation with the Secretary of State, shall coordinate international drug enforcement efforts to decrease the movement of methamphetamine and methamphetamine precursors into the United States.

### **SEC. 102. PENALTIES FOR MANUFACTURE OF LISTED CHEMICALS OUTSIDE THE UNITED STATES WITH INTENT TO IMPORT THEM INTO THE UNITED STATES.**

(a) **UNLAWFUL IMPORTATION.**—Section 1009(a) of the Controlled Substances Import and Export Act (21 U.S.C. 959(a)) is amended—

(1) in the matter before paragraph (1), by inserting "or listed chemical" after "schedule I or II"; and

(2) in paragraphs (1) and (2), by inserting "or chemical" after "substance".

(b) **UNLAWFUL MANUFACTURE OR DISTRIBUTION.**—Paragraphs (1) and (2) of section 1009(b) of the Controlled Substances Import and Export Act (21 U.S.C. 959(b)) are amended by inserting "or listed chemical" after "controlled substance".

(c) **PENALTIES.**—Section 1010(d) of the Controlled Substances Import and Export Act (21 U.S.C. 960(d)) is amended—

(1) in paragraph (5), by striking "or" at the end;

(2) in paragraph (6), by striking the comma at the end and inserting "; or"; and

(3) by adding at the end the following:

4206

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3101

"(7) manufactures, possesses with intent to distribute, or distributes a listed chemical in violation of section 959 of this title."

## TITLE II—PROVISIONS TO CONTROL THE MANUFACTURE OF METH- AMPHETAMINE

### SEC. 201. SEIZURE AND FORFEITURE OF REGULATED CHEMICALS.

(a) PENALTIES FOR SIMPLE POSSESSION.—Section 404 of the Controlled Substances Act (21 U.S.C. 844) is amended—

(1) in subsection (a)—

(A) by adding after the first sentence the following: "It shall be unlawful for any person knowingly or intentionally to possess any list I chemical obtained pursuant to or under authority of a registration issued to that person under section 303 of this title or section 1008 of title III if that registration has been revoked or suspended, if that registration has expired, or if the registrant has ceased to do business in the manner contemplated by his registration."; and

(B) by striking "drug or narcotic" and inserting "drug, narcotic, or chemical" each place it appears; and

(2) in subsection (c), by striking "drug or narcotic" and inserting "drug, narcotic, or chemical".

(b) FORFEITURES.—Section 511(a) of the Controlled Substances Act (21 U.S.C. 881(a)) is amended—

(1) in paragraphs (2) and (6), by inserting "or listed chemical" after "controlled substance" each place it appears; and

(2) in paragraph (9), by—

(A) inserting "dispensed, acquired," after "distributed," both places it appears; and

(B) striking "a felony provision of".

(c) SEIZURE.—Section 607 of the Tariff Act of 1930 (19 U.S.C. 1607) is amended—

(1) in subsection (a)(3), by inserting "or listed chemical" after "controlled substance"; and

(2) by amending subsection (b) to read as follows:

"(b) As used in this section, the terms 'controlled substance' and 'listed chemical' have the meaning given such terms in section 102 of the Controlled Substances Act (21 U.S.C. 802)."

### SEC. 202. STUDY AND REPORT ON MEASURES TO PREVENT SALES OF AGENTS USED IN METHAMPHETAMINE PRODUCTION.

(a) STUDY.—The Attorney General of the United States shall conduct a study on possible measures to effectively prevent the diversion of red phosphorous, iodine, hydrochloric gas, and other agents for use in the production of methamphetamine. Nothing in this section shall preclude the Attorney General from taking any action the Attorney General already is authorized to take with regard to the regulation of listed chemicals under current law.

(b) REPORT.—Not later than January 1, 1998, the Attorney General shall submit a report to the Congress of its findings pursu-

4207

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3102

ant to the study conducted under subsection (a) on the need for and advisability of preventive measures.

(c) CONSIDERATIONS.—In developing recommendations under subsection (b), the Attorney General shall consider—

(1) the use of red phosphorous, iodine, hydrochloric gas, and other agents in the illegal manufacture of methamphetamine;

(2) the use of red phosphorous, iodine, hydrochloric gas, and other agents for legitimate, legal purposes, and the impact any regulations may have on these legitimate purposes; and

(3) comments and recommendations from law enforcement, manufacturers of such chemicals, and the consumers of such chemicals for legitimate, legal purposes.

**SEC. 203. INCREASED PENALTIES FOR MANUFACTURE AND POSSESSION OF EQUIPMENT USED TO MAKE CONTROLLED SUBSTANCES.**

(a) IN GENERAL.—Section 403(d) of the Controlled Substances Act (21 U.S.C. 843(d)) is amended—

(1) by striking "(d) Any person" and inserting "(d)(1) Except as provided in paragraph (2), any person"; and

(2) by adding at the end the following:

"(2) Any person who, with the intent to manufacture or to facilitate the manufacture of methamphetamine, violates paragraph (6) or (7) of subsection (a), shall be sentenced to a term of imprisonment of not more than 10 years, a fine of not more than \$30,000, or both; except that if any person commits such a violation after one or more prior convictions of that person—

"(A) for a violation of paragraph (6) or (7) of subsection (a);

"(B) for a felony under any other provision of this subchapter or subchapter II of this chapter; or

"(C) under any other law of the United States or any State relating to controlled substances or listed chemicals, has become final, such person shall be sentenced to a term of imprisonment of not more than 20 years, a fine of not more than \$60,000, or both."

(b) SENTENCING COMMISSION.—The United States Sentencing Commission shall amend the sentencing guidelines to ensure that the manufacture of methamphetamine in violation of section 403(d)(2) of the Controlled Substances Act, as added by subsection (a), is treated as a significant violation.

**SEC. 204. ADDITION OF IODINE AND HYDROCHLORIC GAS TO LIST II.**

(a) IN GENERAL.—Section 102(35) of the Controlled Substances Act (21 U.S.C. 802(35)) is amended by adding at the end the following:

"(I) Iodine.

"(J) Hydrochloric gas."

(b) IMPORTATION AND EXPORTATION REQUIREMENTS.—(1) Iodine shall not be subject to the requirements for listed chemicals provided in section 1018 of the Controlled Substances Import and Export Act (21 U.S.C. 971).

(2) EFFECT OF EXCEPTION.—The exception made by paragraph (1) shall not limit the authority of the Attorney General to impose the requirements for listed chemicals provided in section 1018 of the Controlled Substances Import and Export Act (21 U.S.C. 971).

4208

**SEC. 206. CIVIL PENALTIES FOR FIRMS THAT SUPPLY PRECURSOR CHEMICALS.**

(a) **OFFENSES.**—Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended—

- (1) in paragraph (9), by striking "or" after the semicolon;
- (2) in paragraph (10), by striking the period and inserting "; or"; and

(3) by adding at the end the following:

"(11) to distribute a laboratory supply to a person who uses, or attempts to use, that laboratory supply to manufacture a controlled substance or a listed chemical, in violation of this title or title III, with reckless disregard for the illegal uses to which such a laboratory supply will be put.

As used in paragraph (11), the term 'laboratory supply' means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer."

(b) **CIVIL PENALTY.**—Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by adding at the end the following:

"(C) In addition to the penalties set forth elsewhere in this title or title III, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than \$250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than \$250,000 or double the last previously imposed penalty, whichever is greater."

**SEC. 208. INJUNCTIVE RELIEF.**

(a) **TEN-YEAR INJUNCTION MAJOR OFFENSES.**—Section 401(f) of the Controlled Substances Act (21 U.S.C. 841(f)) is amended by—

- (1) inserting "manufacture, exportation," after "distribution,"; and
- (2) striking "regulated".

(b) **TEN-YEAR INJUNCTION OTHER OFFENSES.**—Section 403 of the Controlled Substances Act (21 U.S.C. 843) is amended—

- (1) in subsection (e), by—

(A) inserting "manufacture, exportation," after "distribution,"; and

(B) striking "regulated"; and

- (2) by adding at the end the following:

"(f) **INJUNCTIONS.**—(1) In addition to any penalty provided in this section, the Attorney General is authorized to commence a civil action for appropriate declaratory or injunctive relief relating to violations of this section or section 402.

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3104

"(2) Any action under this subsection may be brought in the district court of the United States for the district in which the defendant is located or resides or is doing business.

"(3) Any order or judgment issued by the court pursuant to this subsection shall be tailored to restrain violations of this section or section 402.

"(4) The court shall proceed as soon as practicable to the hearing and determination of such an action. An action under this subsection is governed by the Federal Rules of Civil Procedure except that, if an indictment has been returned against the respondent, discovery is governed by the Federal Rules of Criminal Procedure."

#### SEC. 207. RESTITUTION FOR CLEANUP OF CLANDESTINE LABORATORY SITES.

Section 413 of the Controlled Substances Act (21 U.S.C. 853) is amended by adding at the end the following:

"(q) The court, when sentencing a defendant convicted of an offense under this title or title III involving the manufacture of methamphetamine, may—

"(1) order restitution as provided in sections 3612 and 3664 of title 18, United States Code;

"(2) order the defendant to reimburse the United States for the costs incurred by the United States for the cleanup associated with the manufacture of methamphetamine by the defendant; and

"(3) order restitution to any person injured as a result of the offense as provided in section 3663 of title 18, United States Code."

#### SEC. 208. RECORD RETENTION.

Section 310(a)(1) of the Controlled Substances Act (21 U.S.C. 830(a)(1)) is amended by striking the dash after "transaction" and subparagraphs (A) and (B) and inserting "for two years after the date of the transaction."

#### SEC. 209. TECHNICAL AMENDMENTS.

Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended—

(1) in paragraph (34), by amending subparagraphs (P), (S), and (U) to read as follows:

"(P) Isosafrole.

"(S) N-Methylephedrine.

"(U) Hydriodic acid.; and

(2) in paragraph (35), by amending subparagraph (G) to read as follows:

"(G) 2-Butanone (or Methyl Ethyl Ketone)."

#### SEC. 210. WITHDRAWAL OF REGULATIONS.

The final rule concerning removal of exemption for certain pseudoephedrine products marketed under the Federal Food, Drug, and Cosmetic Act published in the Federal Register of August 7, 1996 (61 FR 40981-40993) is null and void and of no force or effect.

4210



T. 3104

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 310

### TITLE III—INCREASED PENALTIES FOR TRAFFICKING AND MANUFACTURE OF METHAMPHETAMINE AND PRECUR- SORS

#### SEC. 301. PENALTY INCREASES FOR TRAFFICKING IN METHAMPHET- AMINE.

(a) DIRECTIVE TO THE UNITED STATES SENTENCING COMMISSION.—Pursuant to its authority under section 994 of title 28, United States Code, the United States Sentencing Commission shall review and amend its guidelines and its policy statements to provide for increased penalties for unlawful manufacturing, importing, exporting, and trafficking of methamphetamine, and other similar offenses, including unlawful possession with intent to commit any of those offenses, and attempt and conspiracy to commit any of those offenses. The Commission shall submit to Congress explanations therefor and any additional policy recommendations for combating methamphetamine offenses.

(b) IN GENERAL.—In carrying out this section, the Commission shall ensure that the sentencing guidelines and policy statements for offenders convicted of offenses described in subsection (a) and any recommendations submitted under such subsection reflect the heinous nature of such offenses, the need for aggressive law enforcement action to fight such offenses, and the extreme dangers associated with unlawful activity involving methamphetamine, including—

- (1) the rapidly growing incidence of methamphetamine abuse and the threat to public safety such abuse poses;
- (2) the high risk of methamphetamine addiction;
- (3) the increased risk of violence associated with methamphetamine trafficking and abuse; and
- (4) the recent increase in the illegal importation of methamphetamine and precursor chemicals.

#### SEC. 302. ENHANCED PENALTIES FOR OFFENSES INVOLVING CERTAIN LISTED CHEMICALS.

(a) CONTROLLED SUBSTANCES ACT.—Section 401(d) of the Controlled Substances Act (21 U.S.C. 841(d)) is amended by striking "not more than 10 years," and inserting "not more than 20 years in the case of a violation of paragraph (1) or (2) involving a list I chemical or not more than 10 years in the case of a violation of this subsection other than a violation of paragraph (1) or (2) involving a list I chemical,".

(b) CONTROLLED SUBSTANCE IMPORT AND EXPORT ACT.—Section 1010(d) of the Controlled Substance Import and Export Act (21 U.S.C. 960(d)) is amended by striking "not more than 10 years," and inserting "not more than 20 years in the case of a violation of paragraph (1) or (3) involving a list I chemical or not more than 10 years in the case of a violation of this subsection other than a violation of paragraph (1) or (3) involving a list I chemical,".

#### (c) SENTENCING GUIDELINES.—

(1) IN GENERAL.—The United States Sentencing Commission shall, in accordance with the procedures set forth in section 21(a) of the Sentencing Act of 1987, as though the authority of that section had not expired, amend the sentencing guidelines

4211



PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3106

to increase by at least two levels the offense level for offenses involving list I chemicals under—

(A) section 401(d) (1) and (2) of the Controlled Substances Act (21 U.S.C. 841(d) (1) and (2)); and

(B) section 1010(d) (1) and (3) of the Controlled Substance Import and Export Act (21 U.S.C. 960(d) (1) and (3)).

(2) REQUIREMENT.—In carrying out this subsection, the Commission shall ensure that the offense levels for offenses referred to in paragraph (1) are calculated proportionally on the basis of the quantity of controlled substance that reasonably could have been manufactured in a clandestine setting using the quantity of the list I chemical possessed, distributed, imported, or exported.

#### SEC. 303. ENHANCED PENALTY FOR DANGEROUS HANDLING OF CONTROLLED SUBSTANCES: AMENDMENT OF SENTENCING GUIDELINES.

(a) IN GENERAL.—Pursuant to its authority under section 994 of title 28, United States Code, the United States Sentencing Commission shall determine whether the Sentencing Guidelines adequately punish the offenses described in subsection (b) and, if not, promulgate guidelines or amend existing guidelines to provide an appropriate enhancement of the punishment for a defendant convicted of such an offense.

(b) OFFENSE.—The offense referred to in subsection (a) is a violation of section 401(d), 401(g)(1), 403(a)(6), or 403(a)(7) of the Controlled Substances Act (21 U.S.C. 841(d), 841(g)(1), 843(a)(6), and 843(a)(7)), in cases in which in the commission of the offense the defendant violated—

(1) subsection (d) or (e) of section 3008 of the Solid Waste Disposal Act (relating to handling hazardous waste in a manner inconsistent with Federal or applicable State law);

(2) section 103(b) of the Comprehensive Environmental Response, Compensation and Liability Act (relating to failure to notify as to the release of a reportable quantity of a hazardous substance into the environment);

(3) section 301(a), 307(d), 309(c)(2), 309(c)(3), 311(b)(3), or 311(b)(5) of the Federal Water Pollution Control Act (relating to the unlawful discharge of pollutants or hazardous substances, the operation of a source in violation of a pretreatment standard, and the failure to notify as to the release of a reportable quantity of a hazardous substance into the water); or

(4) section 5124 of title 49, United States Code (relating to violations of laws and regulations enforced by the Department of Transportation with respect to the transportation of hazardous material).

### TITLE IV—LEGAL MANUFACTURE, DISTRIBUTION, AND SALE OF PRECURSOR CHEMICALS

#### SEC. 401. DIVERSION OF CERTAIN PRECURSOR CHEMICALS.

(a) IN GENERAL.—Section 102(39) of the Controlled Substances Act (21 U.S.C. 802(39)) is amended—

4212

is

d

e

n

y

3

(1) in subparagraph (A)(iv)(I)(aa), by striking "as" through the semicolon and inserting ", pseudoephedrine or its salts, optical isomers, or salts of optical isomers, or phenylpropanolamine or its salts, optical isomers, or salts of optical isomers unless otherwise provided by regulation of the Attorney General issued pursuant to section 204(e) of this title"; and

(2) in subparagraph (A)(iv)(II), by inserting ", pseudoephedrine, phenylpropanolamine," after "ephedrine".

(b) LEGITIMATE RETAILERS.—Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended—

(1) in paragraph (39)(A)(iv)(I)(aa), by adding before the semicolon the following: ", except that any sale of ordinary over-the-counter pseudoephedrine or phenylpropanolamine products by retail distributors shall not be a regulated transaction (except as provided in section 401(d) of the Comprehensive Methamphetamine Control Act of 1996)";

(2) in paragraph (39)(A)(iv)(II), by adding before the semicolon the following: ", except that the threshold for any sale of products containing pseudoephedrine or phenylpropanolamine products by retail distributors or by distributors required to submit reports by section 310(b)(3) of this title shall be 24 grams of pseudoephedrine or 24 grams of phenylpropanolamine in a single transaction";

(3) by redesignating paragraph (43) relating to felony drug offense as paragraph (44); and

(4) by adding at the end the following:

"(45) The term 'ordinary over-the-counter pseudoephedrine or phenylpropanolamine product' means any product containing pseudoephedrine or phenylpropanolamine that is—

"(A) regulated pursuant to this title; and

"(B)(i) except for liquids, sold in package sizes of not more than 3.0 grams of pseudoephedrine base or 3.0 grams of phenylpropanolamine base, and that is packaged in blister packs, each blister containing not more than two dosage units, or where the use of blister packs is technically infeasible, that is packaged in unit dose packets or pouches; and

"(ii) for liquids, sold in package sizes of not more than 3.0 grams of pseudoephedrine base or 3.0 grams of phenylpropanolamine base.

"(46)(A) The term 'retail distributor' means a grocery store, general merchandise store, drug store, or other entity or person whose activities as a distributor relating to pseudoephedrine or phenylpropanolamine products are limited almost exclusively to sales for personal use, both in number of sales and volume of sales, either directly to walk-in customers or in face-to-face transactions by direct sales.

"(B) For purposes of this paragraph, sale for personal use means the sale of below-threshold quantities in a single transaction to an individual for legitimate medical use.

"(C) For purposes of this paragraph, entities are defined by reference to the Standard Industrial Classification (SIC) code, as follows:

"(i) A grocery store is an entity within SIC code 5411.

"(ii) A general merchandise store is an entity within SIC codes 5300 through 5399 and 5499.

"(iii) A drug store is an entity within SIC code 5912."

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3108

(c) REINSTATEMENT OF LEGAL DRUG EXEMPTION.—Section 204 of the Controlled Substances Act (21 U.S.C. 814) is amended by adding at the end the following new subsection:

"(e) REINSTATEMENT OF EXEMPTION WITH RESPECT TO EPHEDRINE, PSEUDOEPHEDRINE, AND PHENYLPROPANOLAMINE DRUG PRODUCTS.—Pursuant to subsection (d)(1), the Attorney General shall by regulation reinstate the exemption with respect to a particular ephedrine, pseudoephedrine, or phenylpropanolamine drug product if the Attorney General determines that the drug product is manufactured and distributed in a manner that prevents diversion. In making this determination the Attorney General shall consider the factors listed in subsection (d)(2). Any regulation issued pursuant to this subsection may be amended or revoked based on the factors listed in subsection (d)(4)."

(d) REGULATION OF RETAIL SALES.—

(1) PSEUDOEPHEDRINE.—

(A) LIMIT.—

(i) IN GENERAL.—Not sooner than the effective date of this section and subject to the requirements of clause (ii), the Attorney General may establish by regulation a single-transaction limit of 24 grams of pseudoephedrine base for retail distributors. Notwithstanding any other provision of law, the single-transaction threshold quantity for pseudoephedrine-containing compounds may not be lowered beyond that established in this paragraph.

(ii) CONDITIONS.—In order to establish a single-transaction limit of 24 grams of pseudoephedrine base, the Attorney General shall establish, following notice, comment, and an informal hearing that since the date of enactment of this Act there are a significant number of instances where ordinary over-the-counter pseudoephedrine products as established in paragraph (45) of section 102 of the Controlled Substances Act (21 U.S.C. 802(45)), as added by this Act, sold by retail distributors as established in paragraph (46) in section 102 of the Controlled Substances Act (21 U.S.C. 802(46)), are being widely used as a significant source of precursor chemicals for illegal manufacture of a controlled substance for distribution or sale.

(B) VIOLATION.—Any individual or business that violates the thresholds established in this paragraph shall, with respect to the first such violation, receive a warning letter from the Attorney General and, if a business, the business shall be required to conduct mandatory education of the sales employees of the firm with regard to the legal sales of pseudoephedrine. For a second violation occurring within 2 years of the first violation, the business or individual shall be subject to a civil penalty of not more than \$5,000. For any subsequent violation occurring within 2 years of the previous violation, the business or individual shall be subject to a civil penalty not to exceed the amount of the previous civil penalty plus \$5,000.

(2) PHENYLPROPANOLAMINE.—

(A) LIMIT.—

(i) IN GENERAL.—Not sooner than the effective date of this section and subject to the requirements of clause

AT. 3108

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3109

(ii), the Attorney General may establish by regulation a single-transaction limit of 24 grams of phenylpropanolamine base for retail distributors. Notwithstanding any other provision of law, the single-transaction threshold quantity for phenylpropanolamine-containing compounds may not be lowered beyond that established in this paragraph.

(ii) CONDITIONS.—In order to establish a single-transaction limit of 24 grams of phenylpropanolamine base, the Attorney General shall establish, following notice, comment, and an informal hearing, that since the date of enactment of this Act there are a significant number of instances where ordinary over-the-counter phenylpropanolamine products as established in paragraph (45) of section 102 of the Controlled Substances Act (21 U.S.C. 802(45)), as added by this Act, sold by retail distributors as established in paragraph (46) in section 102 of the Controlled Substances Act (21 U.S.C. 802(46)), are being used as a significant source of precursor chemicals for illegal manufacture of a controlled substance in bulk.

(B) VIOLATION.—Any individual or business that violates the thresholds established in this paragraph shall, with respect to the first such violation, receive a warning letter from the Attorney General and, if a business, the business shall be required to conduct mandatory education of the sales employees of the firm with regard to the legal sales of pseudoephedrine. For a second violation occurring within 2 years of the first violation, the business or individual shall be subject to a civil penalty of not more than \$5,000. For any subsequent violation occurring within 2 years of the previous violation, the business or individual shall be subject to a civil penalty not to exceed the amount of the previous civil penalty plus \$5,000.

(3) SIGNIFICANT NUMBER OF INSTANCES.—

(A) IN GENERAL.—For purposes of this subsection, isolated or infrequent use, or use in insubstantial quantities, of ordinary over-the-counter pseudoephedrine or phenylpropanolamine, as defined in section 102(45) of the Controlled Substances Act, as added by section 401(b) of this Act, and sold at the retail level for the illicit manufacture of methamphetamine or amphetamine may not be used by the Attorney General as the basis for establishing the conditions under paragraph (1)(A)(ii) of this subsection, with respect to pseudoephedrine, and paragraph (2)(A)(ii) of this subsection, with respect to phenylpropanolamine.

(B) CONSIDERATIONS AND REPORT.—The Attorney General shall—

(i) in establishing a finding under paragraph (1)(A)(ii) or (2)(A)(ii) of this subsection, consult with the Secretary of Health and Human Services in order to consider the effects on public health that would occur from the establishment of new single transaction limits as provided in such paragraph; and

(ii) upon establishing a finding, transmit a report to the Committees on the Judiciary in both, respectively, the House of Representatives and the Senate

4215



PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3110

in which the Attorney General will provide the factual basis for establishing the new single transaction limits.

(4) DEFINITION OF BUSINESS.—For purposes of this subsection, the term "business" means the entity that makes the direct sale and does not include the parent company of a business not involved in a direct sale regulated by this subsection.

(5) JUDICIAL REVIEW.—Any regulation promulgated by the Attorney General under this section shall be subject to judicial review pursuant to section 507 of the Controlled Substances Act (21 U.S.C. 877).

(e) EFFECT ON THRESHOLDS.—Nothing in the amendments made by subsection (b) or the provisions of subsection (d) shall affect the authority of the Attorney General to modify thresholds (including cumulative thresholds) for retail distributors for products other than ordinary over-the-counter pseudoephedrine or phenylpropanolamine products (as defined in section 102(45) of the Controlled Substances Act, as added by this section) or for non-retail distributors, importers, or exporters.

(f) COMBINATION EPHEDRINE PRODUCTS.—

(1) IN GENERAL.—For the purposes of this section, combination ephedrine products shall be treated the same as pseudoephedrine products, except that—

(A) a single transaction limit of 24 grams shall be effective as of the date of enactment of this Act and shall apply to sales of all combination ephedrine products, notwithstanding the form in which those products are packaged, made by retail distributors or distributors required to submit a report under section 310(b)(3) of the Controlled Substances Act (as added by section 402 of this Act);

(B) for regulated transactions for combination ephedrine products other than sales described in subparagraph (A), the transaction limit shall be—

(i) 1 kilogram of ephedrine base, effective on the date of enactment of this Act; or

(ii) a threshold other than the threshold described in clause (i), if established by the Attorney General not earlier than 1 year after the date of enactment of this Act; and

(C) the penalties provided in subsection (d)(1)(B) of this section shall take effect on the date of enactment of this Act for any individual or business that violates the single transaction limit of 24 grams for combination ephedrine products.

(2) DEFINITION.—For the purposes of this section, the term "combination ephedrine product" means a drug product containing ephedrine or its salts, optical isomers, or salts of optical isomers and therapeutically significant quantities of another active medicinal ingredient.

(g) EFFECTIVE DATE OF THIS SECTION.—Notwithstanding any other provision of this Act, this section shall not apply to the sale of any pseudoephedrine or phenylpropanolamine product prior to 12 months after the date of enactment of this Act, except that, on application of a manufacturer of a particular pseudoephedrine or phenylpropanolamine drug product, the Attorney General may, in her sole discretion, extend such effective date up to an additional

4216

AT. 3110

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3

six months. Notwithstanding any other provision of law, the decision of the Attorney General on such an application shall not be subject to judicial review.

#### SEC. 402. MAIL ORDER RESTRICTIONS.

Section 310(b) of the Controlled Substances Act (21 U.S.C. 830(b)) is amended by adding at the end the following:

"(3) MAIL ORDER REPORTING.—(A) Each regulated person who engages in a transaction with a nonregulated person which—

"(i) involves ephedrine, pseudoephedrine, or phenylpropanolamine (including drug products containing these chemicals); and

"(ii) uses or attempts to use the Postal Service or any private or commercial carrier; shall, on a monthly basis, submit a report of each such transaction conducted during the previous month to the Attorney General in such form, containing such data, and at such times as the Attorney General shall establish by regulation.

"(B) The data required for such reports shall include—

"(i) the name of the purchaser;

"(ii) the quantity and form of the ephedrine, pseudoephedrine, or phenylpropanolamine purchased; and

"(iii) the address to which such ephedrine, pseudoephedrine, or phenylpropanolamine was sent."

### TITLE V—EDUCATION AND RESEARCH

#### SEC. 501. INTERAGENCY METHAMPHETAMINE TASK FORCE.

(a) ESTABLISHMENT.—There is established a "Methamphetamine Interagency Task Force" (referred to as the "interagency task force") which shall consist of the following members:

(1) The Attorney General, or a designee, who shall serve as chair.

(2) 2 representatives selected by the Attorney General.

(3) The Secretary of Education or a designee.

(4) The Secretary of Health and Human Services or a designee.

(5) 2 representatives of State and local law enforcement and regulatory agencies, to be selected by the Attorney General.

(6) 2 representatives selected by the Secretary of Health and Human Services.

(7) 5 nongovernmental experts in drug abuse prevention and treatment to be selected by the Attorney General.

(b) RESPONSIBILITIES.—The interagency task force shall be responsible for designing, implementing, and evaluating the education and prevention and treatment practices and strategies of the Federal Government with respect to methamphetamine and other synthetic stimulants.

(c) MEETINGS.—The interagency task force shall meet at least once every 6 months.

(d) FUNDING.—The administrative expenses of the interagency task force shall be paid out of existing Department of Justice appropriations.

(e) FACA.—The Federal Advisory Committee Act (5 U.S.C. App. 2) shall apply to the interagency task force.



PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 3112

(f) TERMINATION.—The interagency task force shall terminate 4 years after the date of enactment of this Act.

#### SEC. 502. PUBLIC HEALTH MONITORING.

The Secretary of Health and Human Services shall develop a public health monitoring program to monitor methamphetamine abuse in the United States. The program shall include the collection and dissemination of data related to methamphetamine abuse which can be used by public health officials in policy development.

#### SEC. 503. PUBLIC-PRIVATE EDUCATION PROGRAM.

(a) ADVISORY PANEL.—The Attorney General shall establish an advisory panel consisting of an appropriate number of representatives from Federal, State, and local law enforcement and regulatory agencies with experience in investigating and prosecuting illegal transactions of precursor chemicals. The Attorney General shall convene the panel as often as necessary to develop and coordinate educational programs for wholesale and retail distributors of precursor chemicals and supplies.

(b) CONTINUATION OF CURRENT EFFORTS.—The Attorney General shall continue to—

(1) maintain an active program of seminars and training to educate wholesale and retail distributors of precursor chemicals and supplies regarding the identification of suspicious transactions and their responsibility to report such transactions; and

(2) provide assistance to State and local law enforcement and regulatory agencies to facilitate the establishment and maintenance of educational programs for distributors of precursor chemicals and supplies.

#### SEC. 504. SUSPICIOUS ORDERS TASK FORCE.

(a) IN GENERAL.—The Attorney General shall establish a "Suspicious Orders Task Force" (the "Task Force") which shall consist of—

(1) appropriate personnel from the Drug Enforcement Administration (the "DEA") and other Federal, State, and local law enforcement and regulatory agencies with the experience in investigating and prosecuting illegal transactions of listed chemicals and supplies; and

(2) representatives from the chemical and pharmaceutical industry.

(b) RESPONSIBILITIES.—The Task Force shall be responsible for developing proposals to define suspicious orders of listed chemicals, and particularly to develop quantifiable parameters which can be used by registrants in determining if an order is a suspicious order which must be reported to DEA. The quantifiable parameters to be addressed will include frequency of orders, deviations from prior orders, and size of orders. The Task Force shall also recommend provisions as to what types of payment practices or unusual business practices shall constitute prima facie suspicious orders. In evaluating the proposals, the Task Force shall consider effectiveness, cost and feasibility for industry and government, and other relevant factors.

(c) MEETINGS.—The Task Force shall meet at least two times per year and at such other times as may be determined necessary by the Task Force.

4218

3112

PUBLIC LAW 104-237--OCT. 3, 1996

110 STAT. 311

(d) REPORT.—The Task Force shall present a report to the Attorney General on its proposals with regard to suspicious orders and the electronic reporting of suspicious orders within one year of the date of enactment of this Act. Copies of the report shall be forwarded to the Committees of the Senate and House of Representatives having jurisdiction over the regulation of listed chemical and controlled substances.

(e) FUNDING.—The administrative expenses of the Task Force shall be paid out of existing Department of Justice funds or appropriations.

(f) FACA.—The Federal Advisory Committee Act (5 U.S.C. App. 2) shall apply to the Task Force.

(g) TERMINATION.—The Task Force shall terminate upon presentation of its report to the Attorney General, or two years after the date of enactment of this Act, whichever is sooner.

4219

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



## Appendix D

### Suspicious Orders Task Force Operating Charter

**Advisory Committee Operating Charter**  
**Suspicious Orders Task Force**  
**Comprehensive Methamphetamine Control Act of 1996**

**I. Background**

The Suspicious Orders Task Force (the "Task Force") was authorized under Section 504 of the Comprehensive Methamphetamine Control Act (the "MCA") of 1996. The MCA is one of the chemical control amendments to the Controlled Substances Act (the "CSA") of 1970. Further, the Task Force, as established by the MCA, must operate under The Federal Advisory Committee Act (the "Act") (5 U.S.C. App. 2).

**II. The Committee's Official Designation**

This Advisory Committee shall be known as the Suspicious Orders Task Force. (Short form: the Task Force)

**III. Objectives and Scope of Activities**

The Task Force shall be established to develop proposals to provide guidelines to distributors, at various levels, to assist in defining suspicious orders of listed chemicals ("suspicious orders"). Listed chemicals are defined as those 34 List I and List II substances defined in Section 802 of the CSA. Further, the Task Force will have a goal of recommending quantifiable parameters which can be used by registrants in judging if an order is a suspicious order which must be reported to the Drug Enforcement Administration (DEA). Additionally, the Task Force shall explore techniques of reporting the suspicious orders including the electronic transmittal of the information. The quantifiable parameters to be examined shall include, but not be limited to, frequency of orders, deviations from prior orders, and size of orders. The Task Force shall also recommend provisions as to what types of payment practices or unusual business practices shall contribute to the determination of suspicious orders. In evaluating the proposals, the Task Force shall consider effectiveness, cost, and feasibility for industry and government, and other relevant factors. The extent of consideration shall include impact on, and costs to, general business practices of the affected parties.

The Task Force shall limit its area of consideration to domestic issues regarding suspicious orders. The procedures in place to control imports and exports already have provisions for monitoring orders.

Suspicious Orders Task Force 14

2

**Advisory Committee Operating Charter**  
**Suspicious Orders Task Force**  
**Comprehensive Methamphetamine Control Act of 1996**

**VIII. Operating Costs**

The administrative expenses of the Task Force shall be paid out of existing Department of Justice funds, DEA Appropriations. Annual expenses shall include, but not be limited to, the following:

1. Administrative costs.
2. Per Diem and travel expenses for Public Sector participants.
3. Consulting fees for such outside experts as deemed necessary by the Task Force.
4. Private Sector expenses will be borne by the participants and their respective employers.
5. The estimated work-years is three FTE at an annual cost of \$6,000.

All per diem, travel expenses, other expenses, fees, and compensations shall be in accordance with the limitations outlined in the Act. Further, all members of the Task Force serve at the discretion and pleasure of their respective employers. No accommodations will be made for Task Force member's salaries.

**IX. Number of Meetings**

The full Task Force shall hold a minimum of three meetings per year. These meetings shall be in geographically diverse areas so as to allow interested public comment from those concerned with suspicious orders. In accordance with the provisions of the FACA, all meetings will be open and accessible to the general public.

**X. Termination Date**

The Charter shall terminate upon the Task Force's presentation of its final report to the Attorney General or two years after the date of enactment of the MCA (October 3, 1998), whichever is sooner.

**XI. Membership**

The membership of the Task Force shall be in accordance with the provisions of the MCA.

Suspicious Orders Task Force 3

**Advisory Committee Operating Charter**  
Suspicious Orders Task Force  
Comprehensive Methamphetamine Control Act of 1996

**XII. Date of Charter**

The date of this Charter is August 10, 1997.

**XIII. Signatories**



Janet Reno  
Attorney General of The United States  
U.S. Department of Justice

Suspicious Orders Task Force 4





U.S. Department of Justice

Washington, D.C. 20530


SEP -3 1997

The Honorable Orrin G. Hatch  
Chairman  
Committee on the Judiciary  
United States Senate  
Washington, DC 20510

Dear Mr. Chairman:

In accordance with Section 9 of the Federal Advisory Committee Act, 5 U.S.C. App. II, I am enclosing a copy of the Charter as filed with the Library of Congress to establish the Suspicious Orders Task Force. The Task Force was authorized under Section 504 of the Comprehensive Methamphetamine Control Act of 1996 to define suspicious orders of chemicals and develop quantifiable parameters which can be used in determining if an order is a suspicious order which must be reported to the Drug Enforcement Administration. If further information is required, please have a member of your staff contact Janet Dobbs on 514-6755.

Sincerely,

  
Stephen R. Colgate  
Assistant Attorney General  
for Administration

Enclosure



U.S. Department of Justice

Washington, D.C. 20530


SEP -3 1997

Mr. Kenneth Carter  
Library of Congress  
Exchange and Gift Division  
Federal Advisory Committee Desk  
Washington, DC 20540

Dear Mr. Carter:

In accordance with Section 9 of the Federal Advisory Committee Act, 5 U.S.C. App. II, I am enclosing a copy of the Charter to establish the Suspicious Orders Task Force. The Task Force was authorized under Section 504 of the Comprehensive Methamphetamine Control Act of 1996 to define suspicious orders of chemicals and develop quantifiable parameters which can be used in determining if an order is a suspicious order which must be reported to the Drug Enforcement Administration. If further information is required, please have a member of your staff contact Janet Dobbs on 514-6755.

Sincerely,

  
Stephen R. Colgate  
Assistant Attorney General  
for Administration

Enclosure



U.S. Department of Justice

Washington, D.C. 20530


SEP -3 1997

The Honorable Henry J. Hyde  
Chairman  
Committee on the Judiciary  
U.S. House of Representatives  
Washington, DC 20515

Dear Mr. Chairman:

In accordance with Section 9 of the Federal Advisory Committee Act, 5 U.S.C. App. II, I am enclosing a copy of the Charter as filed with the Library of Congress to establish the Suspicious Orders Task Force. The Task Force was authorized under Section 504 of the Comprehensive Methamphetamine Control Act of 1996 to define suspicious orders of chemicals and develop quantifiable parameters which can be used in determining if an order is a suspicious order which must be reported to the Drug Enforcement Administration. If further information is required, please have a member of your staff contact Janet Dobbs on 514-6755.

Sincerely,

  
Stephen R. Colgate  
Assistant Attorney General  
for Administration

Enclosure



U.S. Department of Justice

Washington, D.C. 20530


SEP - 3 1997

Mr. James Dean  
Committee Management Secretariat  
General Services Administration  
18th and F Street, NW Room 7110  
Washington, DC 20006

Dear Mr. Dean:

In accordance with Section 9 of the Federal Advisory Committee Act, 5 U.S.C. App. II, I am enclosing a copy of the Charter as filed with the Library of Congress to establish the Suspicious Orders Task Force. The Task Force was authorized under Section 504 of the Comprehensive Methamphetamine Control Act of 1996 to define suspicious orders of chemicals and develop quantifiable parameters which can be used in determining if an order is a suspicious order which must be reported to the Drug Enforcement Administration. If further information is required, please have a member of your staff contact Janet Dobbs on 514-6755.

Sincerely,

  
Stephen R. Colgate  
Assistant Attorney General  
for Administration

Enclosure

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## Appendix E

### Membership List

The members of the Suspicious Orders Task Force were selected by using the criteria outlined in Section 504 (a)(1) & (2) of the Comprehensive Methamphetamine Control Act of 1996 (Public Law 104-237 enacted October 3, 1996). This composition was tempered with the Federal Advisory Committee Act (5 U.S.C. App. 2) requirement that "the representation be fair and equitable." DEA, as the representative of the Department of Justice, selected various organizations which met the criteria outlined in the applicable statutes and asked them to nominate members to serve on the Task Force. These nominees were then reviewed for appropriateness and sent letters of acceptance. During the course of operation of the Task Force, Ms. Pam Kruger, nominated by the National Association of Drug Diversion Investigators (NADDI) was replaced by Mr. David Hammel at Ms. Kruger's request. Additionally, Mr. Michael Stulberg, representing the American Wholesale Marketers' Association (AWMA), was added to the original twenty members of the Task Force.

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



---

## Suspicious Orders Task Force Membership

### Public Sector Members

Organization: Drug Enforcement Administration (DEA)

S/A William J. Wolf, Jr., Chief *(Chairman)*  
Chemical Operations Section  
DEA, Office of Diversion Control  
600 Army Navy Drive  
Arlington, VA 22202

Voice: 202-307-7204; Fax: 202-307-4702

David Walkup, Diversion Program Manager  
DEA, St Louis Division  
7911 Forsyth Blvd  
Suite 500  
Clayton, MO 63105

Voice: 314-425-3241; Fax: 314-425-3245

S/A Edward John Van Patten  
Group Supervisor  
DEA, Sacramento Resident Office  
1860 Howe Ave, Suite 250  
Sacramento, CA 95825

Voice: 916-566-7188; Fax: 916-566-7177

Organization: National Association of State Controlled Substances Authorities (NASCSA)

David Hale, Agent in Charge  
Oklahoma Bureau of Narcotics  
3313 West 45th Street  
Tulsa, OK 74107

Voice: 918-446-1616; Fax: 918-445-0724



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Organization: Missouri State Highway Patrol

Capt James Keathley  
Missouri State Highway Patrol  
1510 East Elm  
PO Box 568  
Jefferson City, MO 65102

Voice: 573-526-6122; Fax: 573-526-5577

Organization: National Association of Drug Diversion Investigators (NADDI)

Det Pam Kruger

Replaced By:

David Hammel  
Maryland State Police  
1253 Youngs Farm Road  
Annapolis, MD 21403

Voice: 410-268-2447; Fax: 410-268-2431

Organization: National Association of Boards of Pharmacy (NABP)

Richard "Mick" Markuson, Director  
Idaho State Board of Pharmacy  
280 N 8th Street, PO Box 83720  
Boise, ID 83720-0067

Voice: 208-334-2356; Fax: 208-334-3536

Organization: Missouri State's Attorney General's Office

Andrea Spillars, Assistant Attorney General  
PO Box 899  
221 W. High Street  
Jefferson City, MO 65102

Voice: 573-751-4418; Fax: 573-751-5391

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Organization: State of California Bureau of Narcotic Enforcement (CA/BNE)

Katina Kypridakes, Manager  
Precursor Compliance Program  
California Department of Justice  
Bureau of Narcotic Enforcement  
4949 Broadway, Room B-238  
Sacramento, CA 95820

Voice: 916-227-3231; Fax: 916-227-3945

Organization: U.S. Attorney's Office, Southern District of California

Laura Birkmeyer, Chief, Narcotics Enforcement Section  
U.S. Attorney's Office, U.S. Dept. of Justice  
880 Front Street, Room 6293  
San Diego, CA 92101

Voice: 619-557-5481; Fax: 619-557-7053

Organization: International Association of Chiefs of Police

William Berger, Chief  
North Miami Beach Police Department  
16901 NE 19th Avenue  
North Miami Beach, FL 33162

Voice: 305-948-2999; Fax: 305-787-6047

Private Sector Members

Organization: National Community Pharmacist's Association (NCPA)

Ms Sharlea Leatherwood  
4260 N Oak Trfwy  
PO Box 34655  
Kansas City, MO 64116

Voice: 816-453-1050; Fax: 816-453-4055

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Organization: **Chemical Manufacturer's Association (CMA)**

John C Garvey, Manager, Regulatory Affairs  
BASF Corporation  
3000 Continental Drive - North  
Mount Olive, NJ 07828-1234

Voice: 973-426-4843; Fax: 973-426-5315

Ms. Marybeth Kelliher, Senior Manager  
Chemical Manufacturers' Association (CMA)  
1300 Wilson Blvd  
Arlington, VA 22209

Voice: 703-741-5923; Fax: 703-741-6923

Organization: **National Wholesale Druggists' Association (NWDA)**

Douglas Thompson, Sr, VP, Logistics  
McKesson Corp  
1 Post Street  
36th Floor  
San Francisco, CA 94104

Voice: 415-983-8532; Fax: 415-983-9272

Organization: **Food Marketing Institute (FMI)**

Mr. Gale Prince, Director  
Regulatory Compliance  
The Kroger Co.  
1014 Vine Street  
Cincinnati, OH 45202-1100

Voice: 513-762-4209; Fax: 513-762-4372

Organization: **National Association of Chemical Distributors (NACD)**

Mark Kramer, Exec Vice President  
Ellis & Everard, Inc.  
700 Galleria Parkway, Suite 350  
Atlanta, GA 30339

Voice: 770-618-0751; Fax: 770-618-0770

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Peter Ramaley, Director,  
Regulatory Affairs, SOCO Chemical Inc

UPS/FedEx: Pottsville Pike & Huller Lane  
Reading, PA 19605

US Mail: PO Box 13786  
Reading, PA 19612-3786

Voice: 610-926-6100; Fax: 610-926-3070

Organization: National Association of Chain Drug Stores (NACDS)

James Carter, Director  
Loss Prevention & Regulatory Compliance  
Eckert Corporation  
8333 Bryan Dairy Road  
Largo, FL 33777

Voice: 813-395-6300; Fax: 813-395-6314

Organization: Nonprescription Drug Manufacturers Association (NDMA)

Kevin Kraushaar, Associate General Counsel & Director State Government Relations  
Nonprescription Drug Manufacturers Association (NDMA)  
1150 Connecticut Ave NW, Suite 1200  
Washington, D.C. 20036

Voice: 202-429-9260; Fax: 202-223-6835

Organization: American Wholesale Marketers' Association (AWMA)

Michael M. Stulberg, President  
Somody Supply, Inc.  
2701 4th Ave SW  
PO Box 1338  
Willmar, MN 56201

Voice: 320-235-2454; Fax: 320-235-1361

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## Appendix F

### Federal Register Notices

- 1) Formation of the Task Force
- 2) Announcement of the first meeting in Washington, D.C.
- 3) Announcement of the second meeting in San Diego, California
- 4) Announcement of the third meeting in St. Louis, Missouri
- 5) Announcement of the fourth meeting in San Antonio, Texas

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



## Federal Register Notices Formation of the Task Force

DEPARTMENT OF JUSTICE  
Drug Enforcement Administration

Task Force on Suspicious Orders

**AGENCY:** Drug Enforcement Administration (DEA), Justice

**ACTION:** Notice of establishment of Task Force on Suspicious Orders

**SUMMARY:** In accordance with the provisions of the Federal Advisory Committee Act, 5 U.S.C. App 2 (1972), and 41 CFR 101-6.1001-6.1035 (1992), the Administrator of the Drug Enforcement Administration (DEA), with the concurrence of the Attorney General, is establishing a Task Force on Suspicious Orders for the purpose of developing proposals to define suspicious orders of listed chemicals which can be used by registrants in determining if an order is a suspicious order which must be reported to the DEA.

The Task Force is authorized by Public Law 104-237, Section 504 of Subtitle V, Education and Research, the Comprehensive Methamphetamine Control Act of 1996 (the MCA). The specific provisions of the Act state that:

The Task Force shall be responsible for providing the Attorney General with recommendations, advice, and proposals for the establishment of such guidelines that will adequately define suspicious orders of listed chemicals. The Task Force shall limit its area of consideration to domestic issues regarding suspicious orders.

**DATES:** This Task Force is effective September 3, 1997.

**FOR FURTHER INFORMATION CONTACT:** Michael Leser, Program Analyst, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, D.C. 20537, Telephone (202) 307-4026 or Facsimile (202) 307-8570.

### **SUPPLEMENTARY INFORMATION:**

**SCOPE:** Regulated persons are required to report suspicious regulated transactions to DEA pursuant to 21 CFR Section 1310.05(a)(1) and 21 USC Section 830(b)(1)(A). In the past, DEA has had general guidelines which were published in the Chemical Handlers' Manual as



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



to what constituted a suspicious chemical order. The Comprehensive Methamphetamine Control Act of 1996 (MCA) mandated the establishment of the Suspicious Orders Task Force with the express purpose of developing proposals that further define a suspicious order. The scope of discussion of this Task Force shall be limited to enhancements and clarifications of what constitutes a suspicious chemical order that needs to be reported to DEA.

**MEMBERSHIP:** In accordance with the provisions of the MCA, this Task Force will be composed of appropriate personnel with experience in investigating and prosecuting illegal transactions of listed chemicals and supplies, and representatives from the chemical and pharmaceutical industries.

The Task Force will consist of 20 members nominated by the chairman of the Task Force from relevant industry/trade associations and state and local law enforcement agencies.

The composition of the Task Force shall be:

- Two members from the DEA investigative workforce
- One member from the U.S. Attorney's Office, Southern District of California
- One member from the International Association of Chiefs of Police
- One member from The National Association of Diversion Investigators
- One member from the California Bureau of Narcotics Enforcement
- One member from the Missouri State Highway Patrol
- One member from the Missouri Attorney General's Office
- One member from the National Association of Boards of Pharmacy
- One member from the National Association of State Controlled Substances Authorities
- Two members from the Chemical Manufacturers Association
- Two members from the National Association of Chemical Distributors
- One member from the national Non-Prescription Drug Manufacturers' Association
- Four members from the wholesale and retail pharmaceutical marketing associations

The chairman of the Task Force shall reserve the right to add up to two additional members to the Task Force as appropriate.

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



In accordance with the Federal Advisory Committee Act, all meetings of the Task Force shall be open to the public with notice of times and locations appearing in the Federal Register.

Interested parties shall be permitted to attend meetings, appear before the Task Force and present limited verbal statements, and file written statements with Task Force members. Written statements will be taken at any time during the meeting and distributed to the Task Force as soon as feasible. Presenters of written statements are requested to provide 25 copies of the statement to expedite distribution to the Task Force members. If the presenter does not/can not provide the requested copies, the Designated Federal Official (DFO) will make the copies and the Task Force will consider the statement when the copies are available. Verbal comments may be limited in time by the DFO to insure adequate opportunity for testimony by as many presenters as possible.

The Task Force will be advisory only and will provide its report to the Attorney General.

John H. King  
Deputy Assistant Administrator  
Office of Diversion Control

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Federal Register Notices  
Announcement of the first meeting in Washington, D.C.

DEPARTMENT OF JUSTICE  
Drug Enforcement Administration

Task Force on Suspicious Orders Meeting

AGENCY: Drug Enforcement Administration (DEA), Justice

ACTION: Notice of Meeting

SUMMARY: Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), as amended, notice is hereby given that a meeting of the Suspicious Orders Task Force will be held on December 16-17, 1997. The panel will meet from 9:00 a.m. to 5:00 p.m. both days at The Marriot Residence Inn, 550 Army Navy Drive, Arlington, Virginia 22202.

This meeting will be open to the public on a space available basis. Any interested person may observe meetings or portions thereof and shall be permitted to participate in the discussions at the discretion of the meeting chairman and with the approval of the full-time Designated Federal Official (DFO) in attendance.

In addition to presenting limited verbal statements, interested parties shall be permitted to file written statements with Task Force members. Written statements will be taken at any time during the meeting and distributed to the Task Force as soon as feasible. Presenters of written statements are requested to provide 25 copies of the statement to expedite distribution to the Task Force members. If the presenter does not/can not provide the requested copies, the DFO will make the copies and the Task Force will consider the statement when the copies are available. Verbal comments may be limited in time by the DFO to insure adequate opportunity for testimony by as many presenters as possible.

DATES: December 16, 17, 1997.

FOR FURTHER INFORMATION CONTACT: Michael Leser, Program Analyst, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, D.C. 20537, Telephone (202) 307-4026, Facsimile (202) 307-8570.

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



**SUPPLEMENTARY INFORMATION:**

If you need special accommodations due to a disability, please contact the Office of Diversion Control, Drug Enforcement Administration, 600 Army Navy Drive, Arlington, Virginia, 22202, (202) 307-4026 at least seven (7) days prior to the meeting.

John H. King  
Deputy Assistant Administrator  
Office of Diversion Control

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Federal Register Notices  
Announcement of the second meeting in San Diego, California

DEPARTMENT OF JUSTICE  
Drug Enforcement Administration

Task Force on Suspicious Orders Meeting

AGENCY: Drug Enforcement Administration (DEA), Justice

ACTION: Notice of Meeting

SUMMARY: Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), as amended, notice is hereby given that a meeting of the Suspicious Orders Task Force will be held on February 04-05, 1998. The panel will meet from 9:00 a.m. to 5:00 p.m. both days at San Diego California Federal Building, 880 Front Street, San Diego California. All proceedings will be held in the Sixth Floor Auditorium.

This meeting will be open to the public on a space available basis. Any interested person may observe meetings or portions thereof and shall be permitted to participate in the discussions at the discretion of the meeting chairman and with the approval of the full-time Designated Federal Official (DFO) in attendance.

In addition to presenting limited verbal statements, interested parties shall be permitted to file written statements with Task Force members. Written statements will be taken at any time during the meeting and distributed to the Task Force as soon as feasible. Presenters of written statements are requested to provide 25 copies of the statement to expedite distribution to the Task Force members. If the presenter does not/can not provide the requested copies, the DFO will arrange for the copies and the Task Force will consider the statement when the copies are available. Verbal comments may be limited in time by the DFO to insure adequate opportunity for testimony by as many presenters as possible. Any person wishing to submit agenda items or desiring to present formal testimony should contact the DFO at least ten (10) days prior to the meeting.

DATES: February 04, 05, 1998.

FOR FURTHER INFORMATION CONTACT: Michael Leser, Program Analyst, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, D.C. 20537, Telephone (202) 307-4026, Facsimile (202) 307-8570.

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



**SUPPLEMENTARY INFORMATION:**

If you need special accommodations due to a disability, please contact the Office of Diversion Control, Drug Enforcement Administration, 600 Army Navy Drive, Arlington, Virginia, 22202, (202) 307-4026 at least seven (7) days prior to the meeting.

John H. King  
Deputy Assistant Administrator  
Office of Diversion Control



United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Federal Register Notices  
Announcement of the third meeting in St. Louis, Missouri

DEPARTMENT OF JUSTICE  
Drug Enforcement Administration

Task Force on Suspicious Orders Meeting

AGENCY: Drug Enforcement Administration (DEA), Justice

ACTION: Notice of Meeting

SUMMARY: Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), as amended, notice is hereby given that a meeting of the Suspicious Orders Task Force will be held on April 07-08, 1998. The panel will meet from 9:00 a.m. to 5:00 p.m. both days at Adam's Mark Hotel, Fourth and Chestnut, St. Louis, Missouri 63102.

This meeting will be open to the public on a space available basis. Any interested person may observe meetings or portions thereof and shall be permitted to participate in the discussions at the discretion of the meeting chairman and with the approval of the full-time Designated Federal Official (DFO) in attendance.

In addition to presenting limited verbal statements, interested parties shall be permitted to file written statements with Task Force members. Written statements will be taken at any time during the meeting and distributed to the Task Force as soon as feasible. Presenters of written statements are requested to provide 25 copies of the statement to expedite distribution to the Task Force members. If the presenter does not/can not provide the requested copies, the DFO will arrange for the copies and the Task Force will consider the statement when the copies are available. Verbal comments may be limited in time by the DFO to insure adequate opportunity for testimony by as many presenters as possible. Any person wishing to submit agenda items or desiring to present formal testimony should contact the DFO at least ten (10) days prior to the meeting. THIS WILL BE THE LAST OPPORTUNITY FOR THE PUBLIC TO PRESENT TESTIMONY BEFORE THE TASK FORCE. ANY FUTURE MEETINGS WILL BE SOLELY FOR THE PURPOSE OF COMPOSING THE FINISHED REPORT TO BE SUBMITTED TO THE ATTORNEY GENERAL.

DATES: April 07, 08, 1998.

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force

---



**FOR FURTHER INFORMATION CONTACT:** Michael Leser, Program Analyst,  
Liaison and Policy Section, Office of Diversion Control, Drug  
Enforcement Administration, Washington, D.C. 20537, Telephone (202)  
307-4026, Facsimile (202) 307-8570.

**SUPPLEMENTARY INFORMATION:**

If you need special accommodations due to a disability, please  
contact the Office of Diversion Control, Drug Enforcement  
Administration, 600 Army Navy Drive, Arlington, Virginia, 22202,  
(202) 307-4026 at least seven (7) days prior to the meeting.

John H. King  
Deputy Assistant Administrator  
Office of Diversion Control

United States Department of Justice  
Drug Enforcement Administration  
*Office of Diversion Control*  
Suspicious Orders Task Force



Federal Register Notices  
Announcement of the fourth meeting in San Antonio, Texas

DEPARTMENT OF JUSTICE  
Drug Enforcement Administration

Task Force on Suspicious Orders Meeting

**AGENCY:** Drug Enforcement Administration (DEA), Justice

**ACTION:** Notice of Meeting

**SUMMARY:** Pursuant to Section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), as amended, notice is hereby given that a meeting of the Suspicious Orders Task Force (SOTF) will be held on May 19-20, 1998. The panel will meet from 9:00 a.m. to 5:00 p.m. both days at La Mansión del Rio, 112 College Street, San Antonio, Texas.

The purpose of this meeting is to compose the SOTF report that will be submitted to the Attorney General. The meeting will be open to the public on a first-come, first-seated basis. Interested persons are encouraged to attend. Members of the public may submit to the contact person, any time before or after the meeting, written statements to the Task Force. Written comments may be submitted by mail or facsimile, and should contain the writer's name, address and commercial, government, or organizational affiliation, if any.

**DATES:** May 19, 20, 1998.

**FOR FURTHER INFORMATION CONTACT:** Michael Leser, Program Analyst, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, D.C. 20537, Telephone (202) 307-4026, Facsimile (202) 307-8570.

**SUPPLEMENTARY INFORMATION:**

If you need special accommodations due to a disability, please contact the Office of Diversion Control, Drug Enforcement Administration, 600 Army Navy Drive, Arlington, Virginia, 22202, (202) 307-4026 at least seven (7) days prior to the meeting.

John H. King  
Deputy Assistant Administrator  
Office of Diversion Control

SOTF Report Appendix G: 11